0001019056-23-000132.txt : 20230213 0001019056-23-000132.hdr.sgml : 20230213 20230213170542 ACCESSION NUMBER: 0001019056-23-000132 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230213 DATE AS OF CHANGE: 20230213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Modular Medical, Inc. CENTRAL INDEX KEY: 0001074871 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870620495 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41277 FILM NUMBER: 23619715 BUSINESS ADDRESS: STREET 1: 16772 WEST BERNARDO DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92127 BUSINESS PHONE: 858-800-3500 MAIL ADDRESS: STREET 1: 16772 WEST BERNARDO DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92127 FORMER COMPANY: FORMER CONFORMED NAME: BEAR LAKE RECREATION INC DATE OF NAME CHANGE: 19981208 10-Q 1 modular_3q23.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended:

December 31, 2022

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission file number:

001-41277

MODULAR MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada

87-0620495

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

16772 W. Bernardo Drive, San Diego, California

92127

(Address of principal executive offices)

(Zip Code)

(858) 800-3500

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	MODD	The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

x Yes o No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

x Yes o No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Accelerated filer o
Non-accelerated Filer x	Smaller reporting company x
	Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

o Yes x No

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 10,932,098 as of February 8, 2023.

FORM 10-Q
December 31, 2022

TABLE OF CONTENTS

PART I —	FINANCIAL INFORMATION	3

Item 1.	Financial Statements (Unaudited):	3

	Condensed Consolidated Balance Sheets as of December 31, 2022 and March 31, 2022	3

	Condensed Consolidated Statements of Operations for the three and nine months ended December 31, 2022 and 2021	4

	Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the three and nine months ended December 31, 2022 and 2021	5

	Condensed Consolidated Statements of Cash Flows for the nine months ended December 31, 2022 and 2021	6

	Notes to Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

Item 4.	Controls and Procedures	19

PART II —	OTHER INFORMATION	20

Item 1.	Legal Proceedings	20

Item 1A.	Risk Factors	20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20

Item 3.	Defaults Upon Senior Securities	20

Item 4.	Mine Safety Disclosures	20

Item 5.	Other Information	20

Item 6.	Exhibits	21

	Signatures	22

Part I – FINANCIAL INFORMATION

Item 1. Financial Statements

Modular Medical, Inc.
Condensed Consolidated Balance Sheets

	December 31, 2022 (Unaudited)			March 31, 2022
ASSETS

CURRENT ASSETS
Cash and cash equivalents	$	7,690,957		$	9,076,372
Prepaid expenses and other		180,164			313,422
Security deposit		100,000			—
TOTAL CURRENT ASSETS		7,971,121			9,389,794

Property and equipment, net		716,409			235,959
Right of use asset, net		51,312			120,693
Security deposit		—			100,000
TOTAL NON-CURRENT ASSETS		767,721			456,652

TOTAL ASSETS	$	8,738,842		$	9,846,446

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES
Accounts payable	$	382,080		$	299,951
Accrued expenses		255,545			524,891
Short-term lease liability		77,672			144,857
TOTAL CURRENT LIABILITIES		715,297			969,699

Long-term lease liability		—			39,957
TOTAL LIABILITIES		715,297			1,009,656

Commitments and Contingencies (Note 8)

STOCKHOLDERS’ EQUITY
Preferred Stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding		—			—
Common Stock, $0.001 par value, 50,000,000 shares authorized; 10,932,098 and 10,461,898 shares issued and outstanding as of December 31, 2022 and March 31, 2022, respectively		10,932			10,462
Additional paid-in capital		52,900,066			43,406,099
Accumulated deficit		(44,887,453	)		(34,579,771	)
TOTAL STOCKHOLDERS’ EQUITY		8,023,545			8,836,790
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	8,738,842		$	9,846,446

The accompanying notes are an integral part of these condensed consolidated financial statements.

Modular Medical, Inc.

Condensed Consolidated Statements of Operations
(Unaudited)


	Three Months Ended December 31,						Nine Months Ended December 31,
	2022			2021			2022			2021
Operating expenses
Research and development	$	2,196,546		$	1,849,399		$	6,804,069		$	5,742,911
General and administrative		1,161,351			1,981,665			3,502,029			5,156,152
Total operating expenses		3,357,897			3,831,064			10,306,098			10,899,063
Loss from operations		(3,357,897	)		(3,831,064	)		(10,306,098	)		(10,899,063	)

Other income (expense)		(587	)		4			16			368,876
Interest expense		—			(1,010,247	)		—			(2,204,917	)
Loss on debt extinguishment		—			—			—			(1,321,450	)
Loss before income taxes		(3,358,484	)		(4,841,307	)		(10,306,082	)		(14,056,554	)

Provision for income taxes		—			—			1,600			1,600

Net loss	$	(3,358,484	)	$	(4,841,307	)	$	(10,307,682	)	$	(14,058,154	)

Net loss per share
Basic and diluted	$	(0.31	)	$	(0.76	)	$	(0.95	)	$	(2.22	)

Shares used in computing net loss per share
Basic and diluted		10,925,862			6,354,145			10,863,082			6,331,982

The accompanying notes are an integral part of these condensed consolidated financial statements.

Modular Medical, Inc.

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(Unaudited)


	Common Stock				Additional Paid-In		Common Stock		Accumulated			Stockholders’
	Shares		Amount		Capital		Issuable		Deficit			Equity
Balance as of March 31, 2022		10,461,898	$	10,462	$	43,406,099	$	—	$	(34,579,771	)	$	8,836,790
Shares issued for services		348		—		1,576		—		—			1,576
Issuance of common stock and warrants in equity offering, net		449,438		449		7,371,898		—		—			7,372,347
Issuance of common stock under equity incentive plan		2,664		3		13,747		—		—			13,750
Stock-based compensation		—		—		724,819		—		—			724,819
Net loss		—		—		—		—		(3,498,791	)		(3,498,791	)
Balance as of June 30, 2022		10,914,348	$	10,914	$	51,518,139	$	—	$	(38,078,562	)	$	13,450,491
Issuance of common stock under equity incentive plan		11,375		12		50,368		—		—			50,380
Stock-based compensation		—		—		692,060		—		—			692,060
Net loss		—		—		—		—		(3,450,407	)		(3,450,407	)
Balance as of September 30, 2022		10,925,723	$	10,926	$	52,260,567	$	—	$	(41,528,969	)	$	10,742,524
Issuance of common stock under equity incentive plan		6,375		6		12,737		—		—			12,743
Stock-based compensation		—		—		626,762		—		—			626,762
Net loss		—		—		—		—		(3,358,484	)		(3,358,484	)
Balance as of December 31, 2022		10,932,098	$	10,932	$	52,900,066	$	—	$	(44,887,453	)	$	8,023,545

	Common Stock				Additional Paid-In		Common Stock		Accumulated			Stockholders’
	Shares		Amount		Capital		Issuable		Deficit			Deficit
Balance as of March 31, 2021		6,302,050	$	6,302	$	14,665,559	$	—	$	(15,947,010	)	$	(1,275,149	)
Shares issued for services		20,000		20		172,180		—		—			172,200
Warrants issued with convertible notes		—		—		3,700,632		—		—			3,700,632
Issuance of common stock under equity incentive plan		1,836		2		32,495		—		—			32,497
Stock-based compensation		—		—		623,423		—		—			623,423
Net loss		—		—		—		—		(4,835,091	)		(4,835,091	)
Balance as of June 30, 2021		6,323,886	$	6,324	$	19,194,289	$	—	$	(20,782,101	)	$	(1,581,488	)
Stock-based compensation		3,635		4		862,427		—		—			862,431
Net loss		—		—		—		—		(4,381,757	)		(4,381,757	)
Balance as of September 30, 2021		6,327,521	$	6,328	$	20,056,716	$	—	$	(25,163,858	)	$	(5,100,814	)
Private placement of common stock		30,865		31		249,969		—		—			250,000
Shares issued for services		8,334		8		73,748		—		—			73,756
Shares issuable for services		—		—		—		149,994		—			149,994
Shares issued for reverse stock split		1,211		1		—		—		—			1
Stock-based compensation		5,775		6		1,221,729		—		—			1,221,735
Net loss		—		—		—		—		(4,841,307	)		(4,841,307	)
Balance as of December 31, 2021		6,373,706	$	6,374	$	21,602,162	$	149,994	$	(30,005,165	)	$	(8,246,635	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Modular Medical, Inc.

Condensed Consolidated Statements of Cash Flows
(Unaudited)


	Nine Months Ended December 31,
	2022			2021
Cash Flows from operating activities
Net loss	$	(10,307,682	)	$	(14,058,154	)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on PPP note forgiveness		—			(368,780	)
Loss on debt extinguishment		—			1,321,450
Stock-based compensation expense		2,120,513			2,740,086
Depreciation and amortization		92,616			80,268
Shares issued for services		150,412			388,021
Shares issuable for services		—			149,994
Amortization of lease right-of-use asset		69,381			58,404
Change in lease liability		(107,142	)		(92,826	)
Amortization of debt discount		—			1,454,762
Changes in assets and liabilities:
Other assets and prepaid expenses		(15,577	)		(25,995	)
Accounts payable and accrued expenses		(187,217	)		1,223,983
Net cash used in operating activities		(8,184,696	)		(7,128,787	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(573,066	)		(22,779	)
Net cash used in investing activities		(573,066	)		(22,779	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock and warrants, net		7,372,347			—
Proceed from private placement, net of issuance costs		—			250,000
Proceeds from issuance of convertible notes, net		—			4,137,199
Proceeds from issuance of promissory note		—			1,500,000
Net cash provided by financing activities		7,372,347			5,887,199

Net decrease in cash and cash equivalents		(1,385,415	)		(1,264,367	)

Cash and cash equivalents at beginning of period		9,076,372			1,468,465

Cash and cash equivalents at end of period	$	7,690,957		$	204,098

Supplemental disclosure:
Noncash investing and financing activities:
Fair value of detachable warrants issued with convertible notes	$	—		$	3,700,632

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MODULAR MEDICAL, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

NOTE 1 – THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Modular Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras acquired in the merger at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.

The Company is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps for insulin-dependent people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent diabetes to receive their daily insulin in two ways, through a continuous “basal” delivery allowing a small amount of insulin to be in the blood at all times and a “bolus” delivery to address meal time glucose input and to address when the blood glucose level becomes excessively high. By addressing the time and effort required to effectively treat their condition, the Company believes it can address the less technically savvy, less motivated part of the market.

In February 2022, the Company completed a public offering of its equity securities, and its common stock was approved to list on the Nasdaq Capital Market under the symbol “MODD” and began trading there on February 10, 2022.

Liquidity

Financial Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15), Going Concern, requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. If management identifies conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern, management must consider if there are plans that are probable to be implemented, and whether it is probable that the plans will mitigate the conditions or events raising the substantial doubt about the entity’s ability to continue as a going concern. If the substantial doubt is not alleviated after consideration of management’s plans, the entity must include a statement in the notes to the financial statements indicating that there is substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued including: 1) the principal conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, 2) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, and 3) management’s plans to attempt to mitigate the conditions or events causing the substantial doubt about the entity’s ability to continue as a going concern.

The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. The Company’s expected operating losses and cash burn raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company.

The Company’s operating needs include the planned costs to operate its business, fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty.

Basis of Presentation

The Company’s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2023 refers to the fiscal year ending March 31, 2023). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.

The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and with the rules and regulations of the United States Security and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated balance sheet as of March 31, 2022 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with these rules and regulations of the SEC. The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three months ended December 31, 2022 are not necessarily indicative of the results that may be expected for the year ending March 31, 2023 or for any other future period.

Reverse Stock Split

On November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company’s shares of common stock. Such amendment and ratio were previously approved by a majority of the Company’s stockholders and the board of directors. As a result of the reverse stock split, which was effective November 29, 2021, every three shares of the Company’s pre-reverse split outstanding common stock were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stock holders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the reverse split were rounded up to the nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company’s equity incentive plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split. All share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3 reverse stock split.

Use of Estimates

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.

Reportable Segment

The Company operates in one business segment and uses one measurement of profitability for its business.

Research and Development

The Company expenses research and development expenditures as incurred.

General and Administrative

General and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees, and office and other administrative expenses.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure.

Risks and Uncertainties

The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.

The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in- place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted.

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.

Property and Equipment

Property and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended use.

Fixed assets comprised:

Schedule of Fixed Assets

	December 31,			March 31,
	2022			2022
Machinery and equipment	$	487,855		$	346,358
Construction-in-process		427,670			—
Leasehold improvements		139,197			139,197
Total property and equipment		1,054,722			485,555
Less: accumulated depreciation and amortization		(338,313	)		(249,596	)
Total property and equipment, net	$	716,409		$	235,959

Fair Value of Financial Instruments

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.

Right-of-Use Asset

The Company’s right-of-use assets consist of leased assets recognized in accordance with FASB Accounting Standards Codification (ASC) No. 842, Leases which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the condensed consolidated balance sheets and are expensed on a straight-line basis over the lease term in the condensed consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.

Stock-Based Compensation

The Company recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and projected stock option exercise behaviors.

Per-Share Amounts

Basic net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and warrants.

For the nine months ended December 31, 2022 and 2021, the following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive.

Schedule of Anti-Dilutive Shares


	Nine Months Ended December 31,
	2022		2021
Options to purchase common stock		2,174,198		1,967,188
Common stock warrants		7,565,588		767,796
Total		9,739,786		2,734,984

Reclassifications

Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.

Comprehensive Loss

Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and nine months ended December 31, 2022 and 2021, the Company’s comprehensive loss was the same as its net loss.

Recently Issued Accounting Pronouncement

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses. This ASU added a new impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes an allowance for its estimate of expected credit losses and applies to most debt instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that have a low risk of loss. This update is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years for smaller reporting companies. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations and financial position.

NOTE 2 – LEASES

The Company accounts for the lease of its corporate facility in San Diego, California in accordance with ASC No. 842. The 39- month lease term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $12,400 with annual rent increases of approximately 3%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. The right-to-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease payments. A discount rate of 11%, which approximated the Company’s incremental borrowing rate, was used to measure the lease asset and liability. Lease expense is recognized on a straight-line basis over the lease term.

The Company obtained a right-of-use asset of $270,950 in exchange for its obligations under the operating lease. The landlord also provided a lease incentive of approximately $139,000, which was paid to the Company in June 2020, for the Company to make improvements to the leased space. In addition, the Company paid a $100,000 security deposit.

Future minimum payments under the facility operating lease, as of December 31, 2022, are listed in the table below.

Annual Fiscal Years	Operating Lease
2023		39,507
2024		40,692
Less:
Imputed interest		(2,527	)
Present value of lease liabilities	$	77,672

Cash paid for amounts included in the measurement of lease liabilities was $118,521 for the nine months ended December 31, 2022. Rent expense was $80,698 for each of the nine-month periods ended December 31, 2022 and 2021 and $26,930 for each of the three-month periods ended December 31, 2022 and 2021.

NOTE 3 – PPP NOTE

On April 24, 2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was established under the U.S. government’s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note. The full amount of the PPP Note was due in April 2022 and interest accrued on the outstanding principal balance of the PPP Note at a fixed rate of 1.0% per annum, which was deferred for 10 months after the covered period during which the Company used the proceeds.

In May 2021, the Lender and the U.S. Small Business Administration notified the Company that the outstanding principal and accrued interest for the PPP Note was forgiven in full. The Company accounted for the forgiveness of the PPP Note in accordance with ASC Topic 470: Debt (ASC 470), and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the consolidated statement of operations.

NOTE 4 – CONVERTIBLE PROMISSORY NOTES

From February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Note and, collectively, the Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between each holder of an Original Note and the Company, the $2,310,000 of Original Notes and accrued interest thereon as of April 30, 2021 were replaced with $2,360,550 aggregate principal amount of Notes and 2021 Warrants (as defined below). The Company accounted for the replacement of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $1,321,450 and interest expense of $70,647 for unamortized debt issuance costs as of April 30, 2021.

In April and May 2021, pursuant to a securities purchase agreement by and between the Company and each investor (the SPA), the Company sold to investors $4,250,000 aggregate principal amount of convertible promissory notes (the Notes) and warrants to purchase shares of its common stock (the 2021 Warrants). The Notes were unsecured obligations of the Company with each Note having a stated maturity date of 12 months from its issue date and accrued interest at a rate of 12% per annum, payable on maturity. If the Company completed an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise, as defined in the Notes), each Note holder would be required to convert its Adjusted Note Amount (as defined below) into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued interest on a Note, multiplied by (ii) 1.25.

In connection with the issuance of the Notes, the Company issued the 2021 Warrants to purchase in the aggregate 767,796 shares of its common stock at an initial exercise price of $24.00 per share. The fair value of the 2021 Warrants was $3,700,632, of which $2,379,182 was recorded as a debt discount and amortized to interest expense, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated the fair value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of 88.98%, risk-free interest rate of 0.86%, a term of 5.75 years and a dividend yield of zero.

Upon the closing of a public offering in February 2022, which was a Qualified Capital Raise, in accordance with their terms, the Notes converted into 1,511,276 shares of common stock and the holders of the Notes received an additional 1,511,276 common stock purchase warrants with an exercise price of $6.60 per share. In addition, as a result of the February 2022 equity offering, the exercise price of the 767,796 outstanding 2021 Warrants was reduced to $6.00 per share.

NOTE 5 – STOCKHOLDERS’ EQUITY (DEFICIT)

Placements of Common Stock and Warrants

On May 2, 2022, the Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor, pursuant to which the Company sold, in a registered direct offering (the Registered Offering), which closed on May 5, 2022, an aggregate of 449,438 shares (the Shares) of the Company’s common stock, par value $0.001 per share, at a purchase price per Share of $4.45 and pre-funded warrants (the Pre-Funded Warrants) to purchase an aggregate of 1,348,314 shares of common stock at a purchase price per Pre-Funded Warrant of $4.44. The Pre-Funded Warrants will be exercisable immediately on the date of issuance at an exercise price of $0.01 per share and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

In a concurrent private placement under the Purchase Agreement, the Company issued to the Investor warrants (the Private Placement Warrants) to purchase an aggregate of 1,438,202 shares of common stock at an exercise price of $6.60 per share. The Private Placement Warrants will be exercisable beginning on the six-month anniversary of the date of issuance (the Initial Exercise Date) and will expire on the five-year anniversary of the Initial Exercise Date.

Warrants

As of December 31, 2022, the Company had the following warrants outstanding:

Schedule of Warrant Outstanding

Type	Number of Shares		Exercise Price		Expiration Date
Common stock		1,348,314	$	0.01		—
Common stock		767,796	$	6.00		January - February 2027
Common stock		4,011,276	$	6.60		February 2027
Common stock		1,438,202	$	6.60		November 2027
Total		7,565,588

Other

During the nine months ended December 31, 2022 and 2021, the Company issued 348 and 28,334 shares of common stock, respectively, with a fair value of approximately $1,576 and $245,956, respectively, to service providers.

NOTE 6 – STOCK-BASED COMPENSATION

Amended 2017 Equity Incentive Plan

In October 2017, the Company’s board of directors (the Board) approved the 2017 Equity Incentive Plan (the Plan), as amended, with 1,000,000 shares of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance under the Plan by 333,334 and 1,333,334 shares, respectively. Under the Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board.

Stock-Based Compensation Expense

The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant date fair value. As of December 31, 2022, the unamortized compensation cost was $3,443,902 related to stock options and is expected to be recognized as expense over a weighted-average period of approximately 2.07 years.

During the three and nine months ended December 31, 2022, the Company awarded 6,375 and 20,414 shares, respectively, to members of the Board in accordance with the compensation plan for non-employee directors. During the nine months ended December 31, 2022, the Company granted options with 10-year terms to purchase 677,199 shares of its common stock to employees, directors and consultants. The fair value of the options granted and shares awarded was $2,503,979. The following assumptions were used in the fair value calculations of the options granted:

	Three Months Ended December 31,				Nine Months Ended December 31,
	2022		2021		2022		2021
Risk-free interest rates		3.93% - 3.99%		1.26% - 1.36%		2.82% - 4.06%		0.8% - 1.36%
Volatility		149%		197% - 253%		149% - 223%		89% - 370%
Expected life (years)		5.0 - 5.7		5.0 - 6.0		5.0 - 5.7		5.0 - 6.2

The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options, as well as average volatility. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur.

A summary of stock option activity under the Plan is presented below:

Schedule of Stock Option activity

				Options Outstanding
	Shares Available for Grant			Number of Shares			Weighted Average Exercise Prices
Balance at March 31, 2022		989,466			1,650,705		$	6.58
Options granted		(265,634	)		265,634			4.35
Share awards		(2,664	)		—			—
Options cancelled and returned to the Plan		96,668			(96,668	)		7.69
Balance at June 30, 2022		817,836			1,819,671			6.19
Options granted		(241,023	)		241,023			4.35
Share awards		(11,375	)		—			—
Options cancelled and returned to the Plan		30,444			(30,444	)		4.67
Balance at September 30, 2022		595,882			2,030,250			6.00
Options granted		(170,542	)		170,542			2.00
Share awards		(6,375	)		—			—
Options cancelled and returned to the Plan		26,594			(26,594	)		5.82
Balance at December 31, 2022		445,559			2,174,198		$	5.69

There were no stock options exercised during the nine months ended December 31, 2022 and 2021.

The following table summarizes the range of outstanding and exercisable options as of December 31, 2022:

	Options Outstanding					Options Exercisable
Range of Exercise Price		Number Outstanding	Weighted Average Remaining Contractual Life (in Years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price		Aggregate Intrinsic value
$1.98 - $17.70		2,174,198	7.94	$	5.69		1,360,318	$	5.87	$	8,894

The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company’s principal trading market over the exercise price of the option.

The Company is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise of stock options as financing cash flows in the consolidated statements of cash flows. For the nine months ended December 31, 2022 and 2021, there were no such tax benefits associated with the exercise of stock options, as no stock options were exercised.

NOTE 7 – INCOME TAXES

The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance.

The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns for fiscal 2016 to fiscal 2022 may be subject to examination by the U.S. federal and state tax authorities. As of December 31, 2022, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.

NOTE 8 – COMMITMENTS & CONTINGENCIES

Litigations, Claims and Assessments

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

Indemnification

In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company’s consolidated financial statements for the nine months ended December 31, 2022 and 2021 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements, and no claims for payment have been made under such agreements.

Purchase Obligations

The Company's primary purchase obligations include purchase orders for machinery and equipment. At December 31, 2022, the Company had outstanding purchase orders for machinery and equipment and related expenditures of approximately $735,000.

NOTE 9 – SUBSEQUENT EVENTS

New Lease Agreement

On January 5, 2023, the Company entered into a lease agreement (the Thornhill Lease) with Michael Summers (the Lessor) for a new headquarters facility pursuant to which the Company will lease approximately 24,000 square feet of a building located in San Diego, California, commencing on or about February 1, 2023. The monthly base rent is $36,000 for the first 12 months of the lease and will increase by 4% of the prior year’s base rent at the beginning of each 12-month period thereafter. The lease term is 48 months.

Under the Thornhill Lease, the Company will pay the Lessor a monthly fee for its pro-rated share of specified common area charges, including maintenance costs, property taxes and insurance, in addition to base rent. The monthly fee for the common area charges is approximately $10,700 and will be adjusted based on actual costs incurred by the Lessor.

Amended 2017 Equity Incentive Plan

In January 2023, the Company’s stockholders approved an increase in the number of shares reserved for issuance under the Plan by 2,000,000 shares.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the accompanying condensed consolidated financial statements and notes included in this Quarterly Report on Form 10-Q (this Report). This Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which include, without limitation, statements about the market for our technology, our strategy, competition, expected financial performance and capital raising efforts, and other aspects of our business identified in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission on June 28, 2022 and in other reports that we file from time to time with the Securities and Exchange Commission. Any statements about our business, financial results, financial condition and operations contained in this Report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “projects,” or similar expressions are intended to identify forward-looking statements. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described under Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2022. These forward- looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors including, without limitation, the direct and indirect effects of coronavirus disease 2019, or COVID-19 as well as the Russian/Ukraine conflict and inflationary risks, including the risk that the cost of certain of the Company’s materials and product components is increasing, and related issues that may arise therefrom. Many of those factors are outside of our control and could cause actual results to differ materially from those expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

Our fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in this Report, refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2023 refers to the fiscal year ending March 31, 2023). Unless the context requires otherwise, references to “we,” “us,” “our,” and the “Company” refer to Modular Medical, Inc. and its consolidated subsidiary.

Company Overview

We are a development-stage medical device company focused on the design, development and commercialization of an innovative insulin pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our MODD1 product, we seek to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that presently-available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated “super users” and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

Historically, we have financed our operations principally through private placements and public offerings of our common stock and sales of convertible promissory notes. Based on our current operating plan, substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included in Item 1 of this Report are issued exists. Our ability to continue as a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities, to support our future operations. If we are unable to secure additional capital, we will be required to curtail our research and development initiatives and take additional measures to reduce costs. We have provided additional disclosure in Note 1 to the condensed consolidated financial statements in Item 1 of this Report and under Liquidity below.

COVID-19 and Macroeconomic Factors

The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in- place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on our operational and financial performance will depend on future developments, including, without limitation, the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of our control, and cannot be predicted.

Since March 2020, the jurisdiction in which we operate has issued “shelter-in-place” orders from time to time. We have complied with these orders, and, when such orders were in place, minimized business activities at our facility. We have implemented a teleworking policy for our employees and contractors to reduce on-site activity, as necessary. We have and continue to experience longer lead times for certain components used to manufacture initial quantities of our products for our submission to the U.S. Food and Drug Administration (FDA) for approval to commercialize our pump product. We remain diligent in continuing to identify and manage risks to our business given the changing uncertainties related to COVID-19. While we believe that our operations personnel are currently in a position to build an adequate supply of products for our FDA submission, we recognize that unpredictable events could create difficulties in the months ahead. We may not be able to address these difficulties in a timely manner, which could delay our submission to the FDA and negatively impact our business, results of operations, financial condition and cash flows.

We believe that as the COVID-19 pandemic evolves, the direct and indirect impacts of the pandemic on global macroeconomic conditions, as well as conditions specific to us, are becoming more difficult to isolate or quantify. In addition, these direct and indirect factors can make it difficult to isolate and quantify the portion of our costs that are a direct result of the pandemic and costs arising from factors that may have been influenced by the pandemic, such as supply chain constraints, rising inflation, and recessionary fears. We expect these factors and their effects on our operations may persist for a longer period, even after the COVID-19 pandemic has subsided. The continued spread of COVID-19 has also led to disruption and volatility in the global capital markets.

The Russian invasion of Ukraine in February 2022 has led to further economic disruptions. Mounting inflationary costs pressures and recessionary fears have negatively impacted the global economy. During the third quarter of 2022, the U.S. Federal Reserve continued to aggressively address elevated inflation by increasing interest rates. The U.S. Federal reserve increased interest rates by 75 basis points in each of its meetings held in July, September and November 2022, 50 basis points in its meeting held in December 2022, and 25 basis points in its meeting held in February 2023, as inflation remains elevated. We were able to raise additional capital through equity offerings in February 2022 and May 2022, however, we will need to raise additional capital to commercialize our pump product candidate and support our operations in the future. We may be unable to access the capital markets, and additional capital may only be available to us on terms that could be significantly detrimental to our existing stockholders and to our business.

For additional information on risks that could impact our future results, please refer to “Risk Factors” in Part II, Item 1A of this Report.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. On an ongoing basis, we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances. Actual results may differ from these estimates and reported results could differ under different assumptions or conditions. Our significant accounting policies and estimates are disclosed in Note 1 of the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended March 31, 2022. As of December 31, 2022, there have been no material changes to our significant accounting policies and estimates.

Results of Operations

Research and Development

	December 31,				Change
	2022		2021		Fiscal 2022 to Fiscal 2023
Research and development – Three months ended	$	2,196,546	$	1,849,399	$	347,147	18.8	%
Research and development – Nine months ended	$	6,804,069	$	5,742,911	$	1,061,158	18.5	%

Our research and development expenses include personnel, consulting, product prototyping and other costs associated with the development and initial production of our insulin pump product. We expense research and development costs as they are incurred.

Research and development, or R&D, expenses increased for the three and nine months ended December 31, 2022 compared with the same period of fiscal 2021, primarily due to increased engineering and operations personnel costs, prototype and production component and material costs and higher stock-based compensation expenses. The increases in R&D expenses were partially offset by a decrease in consulting costs, as we reduced our utilization of consultants, as we increased our employee headcount and the consultants completed development of aspects of our pump design and features. Our full-time R&D employee headcount increased to 32 at December 31, 2022 from 18 at December 31, 2021. R&D expenses included stock-based compensation expenses of $356,752 and $204,962 for the three months ended December 31, 2022 and 2021, respectively, and $1,034,674 and $459,989 for the nine months ended December 31, 2022 and 2021, respectively. We expect research and development expenses to remain comparable for the remainder of fiscal 2023, as we continue to advance the development of our pump product and develop our manufacturing process.

General and Administrative

	December 31,				Change
	2022		2021		Fiscal 2022 to Fiscal 2023
General and administrative – Three months ended	$	1,161,351	$	1,981,665	$	(820,314	)	(41.4	)%
General and administrative – Nine months ended	$	3,502,029	$	5,156,152	$	(1,654,123	)	(32.1	)%

General and administrative expenses consist primarily of personnel and related overhead costs for finance, human resources, legal, marketing and general management.

General and administrative, or G&A, expenses decreased for the three months ended December 31, 2022 compared with the same period of 2021, primarily as a result of decreased stock-based compensation, personnel and benefit costs and legal fees, which in fiscal 2022 related to our public offering and listing on the Nasdaq that was completed in February 2022. These decreases were partially offset by increased consulting and professional services fees.

G&A expenses decreased for the nine months ended December 31, 2022 compared with the same period of 2021, primarily as a result of decreased stock-based compensation, personnel and benefit costs, consulting and legal fees and marketing costs. These decreases were partially offset by increased accounting fees, travel costs and office-related expenses. Our full-time G&A employee headcount increased to 3 at December 31, 2022 from 2 at December 31, 2021. G&A expenses included stock-based compensation expenses of $282,753 and $1,016,774 for the three months ended December 31, 2022 and 2021, respectively and $1,085,839 and $2,280,098 for the nine months ended December 31, 2022 and 2021, respectively. We expect G&A expenses to remain flat for the remainder of fiscal 2023.

Liquidity and Capital Resources

As a development-stage enterprise, we do not currently have revenues to generate cash flows to cover operating expenses. Since our inception, we have incurred operating losses and negative cash flows in each year due to costs incurred in connection with R&D activities and G&A expenses associated with our operations. For the nine months ended December 31, 2022, we incurred a net loss of approximately $10.3 million. For the years ended March 31, 2022 and 2021, we incurred net losses of approximately $18.6 million and $7.4 million, respectively. At December 31, 2022, we had a cash balance of approximately $7.7 million and an accumulated deficit of approximately $44.9 million. When considered with our current operating plan, these conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that of issuance of the consolidated financial statements included in Item 1 of this Report. Our consolidated financial statements do not include adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. Our ability to continue as a going concern depends on our ability to raise additional capital through the sale of equity or debt securities to support our future operations, and we are currently seeking such additional financing. In May 2022, we completed a registered direct offering of securities for net proceeds of approximately $7.4 million.

Our operating needs include the planned costs to operate our business, including amounts required to fund research and development activities, including clinical studies, working capital and capital expenditures. During the nine months ended December 31, we made capital expenditures of approximately $574,000, as we have begun procuring equipment to develop a low-volume manufacturing production line to build our pump product to demonstrate and develop our manufacturing process. We expect to incur increased capital expenditures for the remainder of fiscal 2023. At December 31, 2022, we had outstanding, non-cancelable purchase orders for production equipment totaling $735,000, and we expect to receive and pay for this equipment over the following six months. Our future capital requirements and the adequacy of our available funds will depend on many factors, including, without limitation, our ability to successfully commercialize our product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product offerings. If we are unable to secure additional capital timely, we will be required to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve our cash.

For the nine months ended December 31, 2022, we used $8,184,696 in operating activities, which primarily resulted from our net loss of $10,307,682, as adjusted for stock-based compensation expenses of $2,120,513, $150,412 for issuances of shares of common stock in exchange for services and depreciation and amortization expenses of $92,616, and increased by net changes in operating lease assets and liabilities of $37,761 and operating assets and liabilities $202,794 and other immaterial adjustments. For the nine months ended December 31, 2021, we used $7,128,787 in operating activities, which primarily resulted from our net loss of $14,058,154, increased for a non-cash gain on the PPP Note extinguishment of $368,780 and net changes in operating lease assets and liabilities of $34,422, as adjusted for changes to operating assets and liabilities of $1,197,988, a loss on debt extinguishment of $1,321,450 stock-based compensation expenses of $2,740,086, $388,021 for issuances of shares of common stock in exchange for services, $149,994 for issuable shares of common stock in exchange for services, depreciation and amortization expenses of $80,268 and interest expense of $1,454,762 for amortization of debt discount.

For the nine months ended December 31, 2022 and 2021, cash used in investing activities of $573,066 and $22,779, respectively, was for the purchase of property and equipment.

Cash provided by financing activities of $7,372,347 for the nine months ended December 31, 2022 was attributable to net proceeds from the issuance of common stock upon completion of an equity offering, net of underwriting fees and issuance costs. Cash provided by financing activities of $5,887,199 for the nine months ended December 31, 2021 was primarily attributable to $4,137,199 of net proceeds from the issuance of our convertible promissory notes, $250,000 from the sale of shares of common stock to officers of the Company and $1,500,000 from the issuance of a promissory bride note.

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements are detailed in Note 1 in the Notes to the Condensed Consolidated Financial Statements included in Item 1 of this Report.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not required.

Item 4. Controls and Procedures

Disclosure Controls and Procedures.

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of our management, including our Chief Executive Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on this evaluation, our management concluded that, as of December 31, 2022, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting.

During the three months ended December 31, 2022, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Part II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. To our knowledge, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of us or our subsidiary, threatened against or affecting us, our common stock, our subsidiary or our subsidiary’s officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

Item 1A. Risk Factors

We face many significant risks in our business, some of which are unknown to us and not presently foreseen. These risks could have a material adverse impact on our business, financial condition and results of operations in the future. There are no material changes to the risk factors set forth under Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2022, which we filed with the SEC on June 28, 2022, and of our Quarterly Report on Form 10Q for the three months ended September 30, 2022, which we filed with the SEC on November 14, 2022, as amended on November 17, 2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Recent Sales of Unregistered Securities

On December 30, 2022, we issued 6,375 shares of our common stock to four of our non-employee directors in accordance with our Outside Director Compensation Plan.

The aforementioned issuances were made pursuant to exemptions from registration pursuant to Section 4(2) and/or Rule 506 of Regulation D of the Securities Act. We made such determinations based upon representations by the purchasers of such securities including, without limitation, that such purchasers were “accredited investors” as defined in the Securities Act.

Item 3. Defaults Upon Senior Securities

There has been no default in the payment of principal, interest, or a sinking or purchase fund installment, or any other material default, with respect to any indebtedness of ours.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit No.		Description of Document
31.1*		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*		Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema
101.CAL		XBRL Taxonomy Extension Calculation Linkbase
101.DEF		XBRL Taxonomy Extension Definition Linkbase
101.LAB		XBRL Taxonomy Extension Label Linkbase
101.PRE		XBRL Taxonomy Extension Presentation Linkbase
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MODULAR MEDICAL, INC.

Date: February 13, 2023	By:	/s/ James E. Besser
		James E. Besser
		Chief Executive Officer
		(Principal Executive Officer)

Date: February 13, 2023	By:	/s/ Paul M. DiPerna
		Paul M. DiPerna
		Chairman, President, Chief Financial Officer and Treasurer
		(Principal Financial Officer)

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, James E. Besser, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Modular Medical, Inc. for the period ended December 31, 2022;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)

Disclosed in this report any change in the registrant’s internal controls over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ James E. Besser		Date: February 13, 2023
James E. Besser
Chief Executive Officer

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul M. DiPerna, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Modular Medical, Inc. for the period ended December 31, 2022;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Paul M. DiPerna		Date: February 13, 2023
Paul M. DiPerna
Chairman, President, Chief Financial Officer and Treasurer

EX-32.1 4 ex32_1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Modular Medical, Inc. (the “Company”) for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of James E. Besser, Chief Executive Officer of the Company, and Paul M. DiPerna, Chairman, President, Chief Financial Officer and Treasurer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities and Exchange Act of 1934, as amended; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and the results of operations of the Company.

By: /s/ James E. Besser		Date: February 13, 2023
James E. Besser
Chief Executive Officer

By: /s/ Paul M. DiPerna		Date: February 13, 2023
Paul M. DiPerna
Chairman, President, Chief Financial Officer and Treasurer

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, or otherwise required, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

EX-101.SCH 5 modd-20221231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - PPP NOTE link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - STOCKHOLDERS’ EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - COMMITMENTS & CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - STOCKHOLDERS’ EQUITY (DEFICIT) (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - PPP NOTE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - STOCKHOLDERS’ EQUITY (DEFICIT) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - STOCK-BASED COMPENSATION (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - STOCK-BASED COMPENSATION (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 modd-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 modd-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 8 modd-20221231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Common Stock Issuable [Member] Retained Earnings [Member] Short-Term Debt, Type [Axis] Convertible Notes Payable [Member] Warrant [Member] Warrant 1 [Member] Warrant 2 [Member] Warrant 3 [Member] Warrant 4 [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Derivative Instrument [Axis] Equity Option [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and cash equivalents Prepaid expenses and other Security deposit TOTAL CURRENT ASSETS Property and equipment, net Right of use asset, net Security deposit TOTAL NON-CURRENT ASSETS TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable Accrued expenses Short-term lease liability TOTAL CURRENT LIABILITIES Long-term lease liability TOTAL LIABILITIES Commitments and Contingencies (Note 8) STOCKHOLDERS’ EQUITY Preferred Stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding Common Stock, $0.001 par value, 50,000,000 shares authorized; 10,932,098 and 10,461,898 shares issued and outstanding as of December 31, 2022 and March 31, 2022, respectively Additional paid-in capital Accumulated deficit TOTAL STOCKHOLDERS’ EQUITY TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] Operating expenses Research and development General and administrative Total operating expenses Loss from operations Other income (expense) Interest expense Loss on debt extinguishment Loss before income taxes Provision for income taxes Net loss Net loss per share Basic and diluted Shares used in computing net loss per share Basic and diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning Balance, Shares Shares issued for services Shares issued for services, Shares Issuance of common stock and warrants in equity offering, net Issuance of common stock and warrants in equity offering, net, Shares Issuance of common stock under equity incentive plan Stock-based compensation, Shares Stock-based compensation Net loss Warrants issued with convertible notes Private placement of common stock Private placement of common stock, Shares Shares issuable for services Shares issued for reverse stock split Shares issued for reverse stock split, Shares Ending balance, value Ending Balance, Shares Statement of Cash Flows [Abstract] Cash Flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Gain on PPP note forgiveness Loss on debt extinguishment Stock-based compensation expense Depreciation and amortization Shares issued for services Shares issuable for services Amortization of lease right-of-use asset Change in lease liability Amortization of debt discount Changes in assets and liabilities: Other assets and prepaid expenses Accounts payable and accrued expenses Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issuance of common stock and warrants, net Proceed from private placement, net of issuance costs Proceeds from issuance of convertible notes, net Proceeds from issuance of promissory note Net cash provided by financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure: Noncash investing and financing activities: Fair value of detachable warrants issued with convertible notes Organization, Consolidation and Presentation of Financial Statements [Abstract] THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Leases [Abstract] LEASES Ppp Note PPP NOTE Debt Disclosure [Abstract] CONVERTIBLE PROMISSORY NOTES Equity [Abstract] STOCKHOLDERS’ EQUITY (DEFICIT) STOCK-BASED COMPENSATION Income Tax Disclosure [Abstract] INCOME TAXES Commitments and Contingencies Disclosure [Abstract] EX-101.PRE 9 modd-20221231_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	9 Months Ended
Cover - shares	Dec. 31, 2022	Feb. 08, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--03-31
Entity File Number	001-41277
Entity Registrant Name	MODULAR MEDICAL, INC.
Entity Central Index Key	0001074871
Entity Tax Identification Number	87-0620495
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	16772 W. Bernardo Drive
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92127
City Area Code	(858)
Local Phone Number	800-3500
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	MODD
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		10,932,098

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 7,690,957	$ 9,076,372
Prepaid expenses and other	180,164	313,422
Security deposit	100,000
TOTAL CURRENT ASSETS	7,971,121	9,389,794
Property and equipment, net	716,409	235,959
Right of use asset, net	51,312	120,693
Security deposit		100,000
TOTAL NON-CURRENT ASSETS	767,721	456,652
TOTAL ASSETS	8,738,842	9,846,446
CURRENT LIABILITIES
Accounts payable	382,080	299,951
Accrued expenses	255,545	524,891
Short-term lease liability	77,672	144,857
TOTAL CURRENT LIABILITIES	715,297	969,699
Long-term lease liability		39,957
TOTAL LIABILITIES	715,297	1,009,656
STOCKHOLDERS’ EQUITY
Preferred Stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding
Common Stock, $0.001 par value, 50,000,000 shares authorized; 10,932,098 and 10,461,898 shares issued and outstanding as of December 31, 2022 and March 31, 2022, respectively	10,932	10,462
Additional paid-in capital	52,900,066	43,406,099
Accumulated deficit	(44,887,453)	(34,579,771)
TOTAL STOCKHOLDERS’ EQUITY	8,023,545	8,836,790
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 8,738,842	$ 9,846,446

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2022	Mar. 31, 2022
Statement of Financial Position [Abstract]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	50,000,000	50,000,000
Common Stock, Shares, Issued	10,932,098	10,461,898
Common Stock, Shares, Outstanding	10,932,098	10,461,898

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Operating expenses
Research and development	$ 2,196,546	$ 1,849,399	$ 6,804,069	$ 5,742,911
General and administrative	1,161,351	1,981,665	3,502,029	5,156,152
Total operating expenses	3,357,897	3,831,064	10,306,098	10,899,063
Loss from operations	(3,357,897)	(3,831,064)	(10,306,098)	(10,899,063)
Other income (expense)	(587)	4	16	368,876
Interest expense		(1,010,247)		(2,204,917)
Loss on debt extinguishment				(1,321,450)
Loss before income taxes	(3,358,484)	(4,841,307)	(10,306,082)	(14,056,554)
Provision for income taxes			1,600	1,600
Net loss	$ (3,358,484)	$ (4,841,307)	$ (10,307,682)	$ (14,058,154)
Net loss per share
Basic and diluted	$ (0.31)	$ (0.76)	$ (0.95)	$ (2.22)
Shares used in computing net loss per share
Basic and diluted	10,925,862	6,354,145	10,863,082	6,331,982

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Issuable [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Mar. 31, 2021	$ 6,302	$ 14,665,559		$ (15,947,010)	$ (1,275,149)
Beginning Balance, Shares at Mar. 31, 2021	6,302,050
Shares issued for services	$ 20	172,180			172,200
Shares issued for services, Shares	20,000
Issuance of common stock under equity incentive plan	$ 2	32,495			32,497
Stock-based compensation, Shares	1,836
Stock-based compensation		623,423			623,423
Net loss				(4,835,091)	(4,835,091)
Warrants issued with convertible notes		3,700,632			3,700,632
Ending balance, value at Jun. 30, 2021	$ 6,324	19,194,289		(20,782,101)	(1,581,488)
Ending Balance, Shares at Jun. 30, 2021	6,323,886
Beginning balance, value at Mar. 31, 2021	$ 6,302	14,665,559		(15,947,010)	(1,275,149)
Beginning Balance, Shares at Mar. 31, 2021	6,302,050
Shares issued for services					$ 245,956
Shares issued for services, Shares					28,334
Issuance of common stock and warrants in equity offering, net
Net loss					(14,058,154)
Warrants issued with convertible notes					3,700,632
Ending balance, value at Dec. 31, 2021	$ 6,374	21,602,162	149,994	(30,005,165)	(8,246,635)
Ending Balance, Shares at Dec. 31, 2021	6,373,706
Beginning balance, value at Jun. 30, 2021	$ 6,324	19,194,289		(20,782,101)	(1,581,488)
Beginning Balance, Shares at Jun. 30, 2021	6,323,886
Stock-based compensation, Shares	3,635
Stock-based compensation	$ 4	862,427			862,431
Net loss				(4,381,757)	(4,381,757)
Ending balance, value at Sep. 30, 2021	$ 6,328	20,056,716		(25,163,858)	(5,100,814)
Ending Balance, Shares at Sep. 30, 2021	6,327,521
Shares issued for services	$ 8	73,748			73,756
Shares issued for services, Shares	8,334
Stock-based compensation, Shares	5,775
Stock-based compensation	$ 6	1,221,729			1,221,735
Net loss				(4,841,307)	(4,841,307)
Private placement of common stock	$ 31	249,969			250,000
Private placement of common stock, Shares	30,865
Shares issuable for services			149,994		149,994
Shares issued for reverse stock split	$ 1				1
Shares issued for reverse stock split, Shares	1,211
Ending balance, value at Dec. 31, 2021	$ 6,374	21,602,162	149,994	(30,005,165)	(8,246,635)
Ending Balance, Shares at Dec. 31, 2021	6,373,706
Beginning balance, value at Mar. 31, 2022	$ 10,462	43,406,099		(34,579,771)	8,836,790
Beginning Balance, Shares at Mar. 31, 2022	10,461,898
Shares issued for services		1,576			1,576
Shares issued for services, Shares	348
Issuance of common stock and warrants in equity offering, net	$ 449	7,371,898			7,372,347
Issuance of common stock and warrants in equity offering, net, Shares	449,438
Issuance of common stock under equity incentive plan	$ 3	13,747			13,750
Stock-based compensation, Shares	2,664
Stock-based compensation		724,819			724,819
Net loss				(3,498,791)	(3,498,791)
Ending balance, value at Jun. 30, 2022	$ 10,914	51,518,139		(38,078,562)	13,450,491
Ending Balance, Shares at Jun. 30, 2022	10,914,348
Beginning balance, value at Mar. 31, 2022	$ 10,462	43,406,099		(34,579,771)	8,836,790
Beginning Balance, Shares at Mar. 31, 2022	10,461,898
Shares issued for services					$ 1,576
Shares issued for services, Shares					348
Issuance of common stock and warrants in equity offering, net					$ 7,372,347
Net loss					(10,307,682)
Warrants issued with convertible notes
Ending balance, value at Dec. 31, 2022	$ 10,932	52,900,066		(44,887,453)	8,023,545
Ending Balance, Shares at Dec. 31, 2022	10,932,098
Beginning balance, value at Jun. 30, 2022	$ 10,914	51,518,139		(38,078,562)	13,450,491
Beginning Balance, Shares at Jun. 30, 2022	10,914,348
Issuance of common stock under equity incentive plan	$ 12	50,368			50,380
Stock-based compensation, Shares	11,375
Stock-based compensation		692,060			692,060
Net loss				(3,450,407)	(3,450,407)
Ending balance, value at Sep. 30, 2022	$ 10,926	52,260,567		(41,528,969)	10,742,524
Ending Balance, Shares at Sep. 30, 2022	10,925,723
Issuance of common stock under equity incentive plan	$ 6	12,737			12,743
Stock-based compensation, Shares	6,375
Stock-based compensation		626,762			626,762
Net loss				(3,358,484)	(3,358,484)
Ending balance, value at Dec. 31, 2022	$ 10,932	$ 52,900,066		$ (44,887,453)	$ 8,023,545
Ending Balance, Shares at Dec. 31, 2022	10,932,098

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from operating activities
Net loss	$ (10,307,682)	$ (14,058,154)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on PPP note forgiveness		(368,780)
Loss on debt extinguishment		1,321,450
Stock-based compensation expense	2,120,513	2,740,086
Depreciation and amortization	92,616	80,268
Shares issued for services	150,412	388,021
Shares issuable for services		149,994
Amortization of lease right-of-use asset	69,381	58,404
Change in lease liability	(107,142)	(92,826)
Amortization of debt discount		1,454,762
Changes in assets and liabilities:
Other assets and prepaid expenses	(15,577)	(25,995)
Accounts payable and accrued expenses	(187,217)	1,223,983
Net cash used in operating activities	(8,184,696)	(7,128,787)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(573,066)	(22,779)
Net cash used in investing activities	(573,066)	(22,779)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock and warrants, net	7,372,347
Proceed from private placement, net of issuance costs		250,000
Proceeds from issuance of convertible notes, net		4,137,199
Proceeds from issuance of promissory note		1,500,000
Net cash provided by financing activities	7,372,347	5,887,199
Net decrease in cash and cash equivalents	(1,385,415)	(1,264,367)
Cash and cash equivalents at beginning of period	9,076,372	1,468,465
Cash and cash equivalents at end of period	7,690,957	204,098
Noncash investing and financing activities:
Fair value of detachable warrants issued with convertible notes		$ 3,700,632

XML 16 R7.htm IDEA: XBRL DOCUMENT

THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Liquidity

Basis of Presentation

Reverse Stock Split

Use of Estimates

Reportable Segment

The Company operates in one business segment and uses one measurement of profitability for its business.

Research and Development

The Company expenses research and development expenditures as incurred.

General and Administrative

General and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees, and office and other administrative expenses.

Concentration of Credit Risk

Risks and Uncertainties

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.

Property and Equipment

Fixed assets comprised:

Schedule of Fixed Assets

	December 31,			March 31,
	2022			2022
Machinery and equipment	$	487,855		$	346,358
Construction-in-process		427,670			—
Leasehold improvements		139,197			139,197
Total property and equipment		1,054,722			485,555
Less: accumulated depreciation and amortization		(338,313	)		(249,596	)
Total property and equipment, net	$	716,409		$	235,959

Fair Value of Financial Instruments

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.

Right-of-Use Asset

Stock-Based Compensation

Per-Share Amounts

Schedule of Anti-Dilutive Shares


	Nine Months Ended December 31,
	2022		2021
Options to purchase common stock		2,174,198		1,967,188
Common stock warrants		7,565,588		767,796
Total		9,739,786		2,734,984

Reclassifications

Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.

Comprehensive Loss

Recently Issued Accounting Pronouncement

XML 17 R8.htm IDEA: XBRL DOCUMENT

LEASES

9 Months Ended

Dec. 31, 2022

Leases [Abstract]

LEASES

NOTE 2 – LEASES

Future minimum payments under the facility operating lease, as of December 31, 2022, are listed in the table below.

Annual Fiscal Years	Operating Lease
2023		39,507
2024		40,692
Less:
Imputed interest		(2,527	)
Present value of lease liabilities	$	77,672

XML 18 R9.htm IDEA: XBRL DOCUMENT

PPP NOTE

9 Months Ended

Dec. 31, 2022

Ppp Note

PPP NOTE

NOTE 3 – PPP NOTE

XML 19 R10.htm IDEA: XBRL DOCUMENT

CONVERTIBLE PROMISSORY NOTES

9 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

CONVERTIBLE PROMISSORY NOTES

NOTE 4 – CONVERTIBLE PROMISSORY NOTES

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 20 R11.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ EQUITY (DEFICIT)

9 Months Ended

Dec. 31, 2022

Equity [Abstract]

STOCKHOLDERS’ EQUITY (DEFICIT)

NOTE 5 – STOCKHOLDERS’ EQUITY (DEFICIT)

Placements of Common Stock and Warrants

Warrants

As of December 31, 2022, the Company had the following warrants outstanding:

Schedule of Warrant Outstanding

Type	Number of Shares		Exercise Price		Expiration Date
Common stock		1,348,314	$	0.01		—
Common stock		767,796	$	6.00		January - February 2027
Common stock		4,011,276	$	6.60		February 2027
Common stock		1,438,202	$	6.60		November 2027
Total		7,565,588

Other

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 21 R12.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION

9 Months Ended

Dec. 31, 2022

Equity [Abstract]

STOCK-BASED COMPENSATION

NOTE 6 – STOCK-BASED COMPENSATION

Amended 2017 Equity Incentive Plan

Stock-Based Compensation Expense

	Three Months Ended December 31,				Nine Months Ended December 31,
	2022		2021		2022		2021
Risk-free interest rates		3.93% - 3.99%		1.26% - 1.36%		2.82% - 4.06%		0.8% - 1.36%
Volatility		149%		197% - 253%		149% - 223%		89% - 370%
Expected life (years)		5.0 - 5.7		5.0 - 6.0		5.0 - 5.7		5.0 - 6.2

A summary of stock option activity under the Plan is presented below:

Schedule of Stock Option activity

				Options Outstanding
	Shares Available for Grant			Number of Shares			Weighted Average Exercise Prices
Balance at March 31, 2022		989,466			1,650,705		$	6.58
Options granted		(265,634	)		265,634			4.35
Share awards		(2,664	)		—			—
Options cancelled and returned to the Plan		96,668			(96,668	)		7.69
Balance at June 30, 2022		817,836			1,819,671			6.19
Options granted		(241,023	)		241,023			4.35
Share awards		(11,375	)		—			—
Options cancelled and returned to the Plan		30,444			(30,444	)		4.67
Balance at September 30, 2022		595,882			2,030,250			6.00
Options granted		(170,542	)		170,542			2.00
Share awards		(6,375	)		—			—
Options cancelled and returned to the Plan		26,594			(26,594	)		5.82
Balance at December 31, 2022		445,559			2,174,198		$	5.69

There were no stock options exercised during the nine months ended December 31, 2022 and 2021.

The following table summarizes the range of outstanding and exercisable options as of December 31, 2022:

	Options Outstanding					Options Exercisable
Range of Exercise Price		Number Outstanding	Weighted Average Remaining Contractual Life (in Years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price		Aggregate Intrinsic value
$1.98 - $17.70		2,174,198	7.94	$	5.69		1,360,318	$	5.87	$	8,894

The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company’s principal trading market over the exercise price of the option.

XML 22 R13.htm IDEA: XBRL DOCUMENT

INCOME TAXES

9 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 7 – INCOME TAXES

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 23 R14.htm IDEA: XBRL DOCUMENT

COMMITMENTS & CONTINGENCIES

9 Months Ended

Dec. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS & CONTINGENCIES

NOTE 8 – COMMITMENTS & CONTINGENCIES

Litigations, Claims and Assessments

Indemnification

Purchase Obligations

XML 24 R15.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

9 Months Ended

Dec. 31, 2022

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 9 – SUBSEQUENT EVENTS

New Lease Agreement

Amended 2017 Equity Incentive Plan

In January 2023, the Company’s stockholders approved an increase in the number of shares reserved for issuance under the Plan by 2,000,000 shares.

XML 25 R16.htm IDEA: XBRL DOCUMENT

THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Liquidity

Basis of Presentation

Reverse Stock Split

Use of Estimates

Reportable Segment

The Company operates in one business segment and uses one measurement of profitability for its business.

Research and Development

The Company expenses research and development expenditures as incurred.

General and Administrative

General and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees, and office and other administrative expenses.

Concentration of Credit Risk

Risks and Uncertainties

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.

Property and Equipment

Fixed assets comprised:

Schedule of Fixed Assets

	December 31,			March 31,
	2022			2022
Machinery and equipment	$	487,855		$	346,358
Construction-in-process		427,670			—
Leasehold improvements		139,197			139,197
Total property and equipment		1,054,722			485,555
Less: accumulated depreciation and amortization		(338,313	)		(249,596	)
Total property and equipment, net	$	716,409		$	235,959

Fair Value of Financial Instruments

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.

Right-of-Use Asset

Right-of-Use Asset

Stock-Based Compensation

Per-Share Amounts

Schedule of Anti-Dilutive Shares


	Nine Months Ended December 31,
	2022		2021
Options to purchase common stock		2,174,198		1,967,188
Common stock warrants		7,565,588		767,796
Total		9,739,786		2,734,984

Reclassifications

Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.

Comprehensive Loss

Recently Issued Accounting Pronouncement

XML 26 R17.htm IDEA: XBRL DOCUMENT

THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Fixed Assets

Fixed assets comprised:

Schedule of Fixed Assets

THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

	December 31,			March 31,
	2022			2022
Machinery and equipment	$	487,855		$	346,358
Construction-in-process		427,670			—
Leasehold improvements		139,197			139,197
Total property and equipment		1,054,722			485,555
Less: accumulated depreciation and amortization		(338,313	)		(249,596	)
Total property and equipment, net	$	716,409		$	235,959

Schedule of Anti-Dilutive Shares

THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)


	Nine Months Ended December 31,
	2022		2021
Options to purchase common stock		2,174,198		1,967,188
Common stock warrants		7,565,588		767,796
Total		9,739,786		2,734,984

XML 27 R18.htm IDEA: XBRL DOCUMENT

LEASES (Tables)

9 Months Ended

Dec. 31, 2022

Leases [Abstract]

Schedule of Future minimum Lease Payment

Future minimum payments under the facility operating lease, as of December 31, 2022, are listed in the table below.

LEASES

Annual Fiscal Years	Operating Lease
2023		39,507
2024		40,692
Less:
Imputed interest		(2,527	)
Present value of lease liabilities	$	77,672

XML 28 R19.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ EQUITY (DEFICIT) (Tables)

9 Months Ended

Dec. 31, 2022

Equity [Abstract]

Schedule of Warrant Outstanding

As of December 31, 2022, the Company had the following warrants outstanding:

Schedule of Warrant Outstanding

STOCKHOLDERS' EQUITY (DEFICIT)

Type	Number of Shares		Exercise Price		Expiration Date
Common stock		1,348,314	$	0.01		—
Common stock		767,796	$	6.00		January - February 2027
Common stock		4,011,276	$	6.60		February 2027
Common stock		1,438,202	$	6.60		November 2027
Total		7,565,588

XML 29 R20.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Dec. 31, 2022

Equity [Abstract]

Schedule of Fair value Assumptions of Options

STOCK-BASED COMPENSATION

	Three Months Ended December 31,				Nine Months Ended December 31,
	2022		2021		2022		2021
Risk-free interest rates		3.93% - 3.99%		1.26% - 1.36%		2.82% - 4.06%		0.8% - 1.36%
Volatility		149%		197% - 253%		149% - 223%		89% - 370%
Expected life (years)		5.0 - 5.7		5.0 - 6.0		5.0 - 5.7		5.0 - 6.2

Schedule of Stock Option activity

A summary of stock option activity under the Plan is presented below:

Schedule of Stock Option activity

STOCK-BASED COMPENSATION (Details 2)

				Options Outstanding
	Shares Available for Grant			Number of Shares			Weighted Average Exercise Prices
Balance at March 31, 2022		989,466			1,650,705		$	6.58
Options granted		(265,634	)		265,634			4.35
Share awards		(2,664	)		—			—
Options cancelled and returned to the Plan		96,668			(96,668	)		7.69
Balance at June 30, 2022		817,836			1,819,671			6.19
Options granted		(241,023	)		241,023			4.35
Share awards		(11,375	)		—			—
Options cancelled and returned to the Plan		30,444			(30,444	)		4.67
Balance at September 30, 2022		595,882			2,030,250			6.00
Options granted		(170,542	)		170,542			2.00
Share awards		(6,375	)		—			—
Options cancelled and returned to the Plan		26,594			(26,594	)		5.82
Balance at December 31, 2022		445,559			2,174,198		$	5.69

Schedule of Outstanding and Exercisable Option, Range

The following table summarizes the range of outstanding and exercisable options as of December 31, 2022:

STOCK-BASED COMPENSATION (Details 3)

	Options Outstanding					Options Exercisable
Range of Exercise Price		Number Outstanding	Weighted Average Remaining Contractual Life (in Years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price		Aggregate Intrinsic value
$1.98 - $17.70		2,174,198	7.94	$	5.69		1,360,318	$	5.87	$	8,894

XML 30 R21.htm IDEA: XBRL DOCUMENT

THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Machinery and equipment	$ 487,855	$ 346,358
Construction-in-process	427,670
Leasehold improvements	139,197	139,197
Total property and equipment	1,054,722	485,555
Less: accumulated depreciation and amortization	(338,313)	(249,596)
Total property and equipment, net	$ 716,409	$ 235,959

XML 31 R22.htm IDEA: XBRL DOCUMENT

THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - shares	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Options to purchase common stock	2,174,198	1,967,188
Common stock warrants	7,565,588	767,796
Total	9,739,786	2,734,984

XML 32 R23.htm IDEA: XBRL DOCUMENT

THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	Nov. 24, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stockholders' Equity, Reverse Stock Split	On November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company’s shares of common stock.

XML 33 R24.htm IDEA: XBRL DOCUMENT

LEASES (Details)	Dec. 31, 2022 USD ($)
Leases [Abstract]
2023	$ 39,507
2024	40,692
Imputed interest	(2,527)
Present value of lease liabilities	$ 77,672

XML 34 R25.htm IDEA: XBRL DOCUMENT

LEASES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
LEASES (Details Narrative) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Cash Paid for Lease Liabilities	$ 118,521		$ 118,521
Operating Leases, Rent Expense	$ 26,930	$ 26,930	$ 80,698	$ 80,698

XML 35 R26.htm IDEA: XBRL DOCUMENT

PPP NOTE (Details Narrative)	Apr. 24, 2020 USD ($)
Ppp Note
Unsecured Debt, Current	$ 368,780

XML 36 R27.htm IDEA: XBRL DOCUMENT

CONVERTIBLE PROMISSORY NOTES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	May 31, 2021
Short-Term Debt [Line Items]
Gain (Loss) on Extinguishment of Debt	$ 1,321,450				$ 1,321,450
Amortization of Debt Issuance Costs	70,647
Warrant [Member]
Short-Term Debt [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate					88.98%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate					0.86%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term					5 years 9 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate					0.00%
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Convertible Notes Payable	$ 2,310,000					$ 4,250,000

XML 37 R28.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (DEFICIT) (Details) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of Warrant or Right, Outstanding	7,565,588	767,796
Warrant 1 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of Warrant or Right, Outstanding	1,348,314
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price	$ 0.01
Warrant 2 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of Warrant or Right, Outstanding	767,796
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price	$ 6.00
Warrant 3 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of Warrant or Right, Outstanding	4,011,276
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price	$ 6.60
Warrant 4 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of Warrant or Right, Outstanding	1,438,202
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price	$ 6.60

XML 38 R29.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ EQUITY (DEFICIT) (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Stock Issued During Period, Shares, Issued for Services				348	28,334
Stock Issued During Period, Value, Issued for Services	$ 1,576	$ 73,756	$ 172,200	$ 1,576	$ 245,956

XML 39 R30.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details)	3 Months Ended		9 Months Ended
STOCK-BASED COMPENSATION (Details)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate	149.00%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	3.93%	1.26%	2.82%	0.80%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate		197.00%	149.00%	89.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term	5 years	5 years	5 years	5 years
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	3.99%	1.36%	4.06%	1.36%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate		253.00%	223.00%	370.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term	5 years 8 months 12 days	6 years	5 years 8 months 12 days	6 years 2 months 12 days

XML 40 R31.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details 2) - $ / shares	3 Months Ended
STOCK-BASED COMPENSATION (Details 2) - $ / shares	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022
Offsetting Assets [Line Items]
Options to purchase common stock	2,174,198
Equity Option [Member]
Offsetting Assets [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant	595,882	817,836	989,466
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance	2,030,250	1,819,671	1,650,705
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 6.00	$ 6.19	$ 6.58
Granted	(170,542)	(241,023)	(265,634)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross	170,542	241,023	265,634
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 2.00	$ 4.35	$ 4.35
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards]	(6,375)	(11,375)	(2,664)
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant]	26,594	30,444	96,668
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period	(26,594)	(30,444)	(96,668)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price	$ 5.82	$ 4.67	$ 7.69
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant	445,559	595,882	817,836
Options to purchase common stock	2,174,198	2,030,250	1,819,671
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 5.69	$ 6.00	$ 6.19

XML 41 R32.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details 3) - USD ($)	3 Months Ended
STOCK-BASED COMPENSATION (Details 3) - USD ($)	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Offsetting Assets [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	2,174,198				1,967,188
Equity Option [Member]
Offsetting Assets [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	2,174,198	2,030,250	1,819,671	1,650,705
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 11 months 8 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 5.69	$ 6.00	$ 6.19	$ 6.58
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	1,360,318
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 5.87
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	$ 8,894
Equity Option [Member] \| Minimum [Member]
Offsetting Assets [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price	$ 1.98
Equity Option [Member] \| Maximum [Member]
Offsetting Assets [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price	$ 17.70

XML 42 R33.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details Narrative) - shares	1 Months Ended
STOCK-BASED COMPENSATION (Details Narrative) - shares	Oct. 31, 2017	Aug. 31, 2021	Jan. 31, 2020
Equity [Abstract]
Shares Approved under Equity Incentive Plan	1,000,000
Common Stock, Capital Shares Reserved for Future Issuance		1,333,334	333,334

XML 43 R34.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - shares	1 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - shares	Jan. 31, 2023	Oct. 31, 2017
Subsequent Event [Line Items]
Shares approved under Equity Incentive Plan		1,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Shares approved under Equity Incentive Plan	2,000,000

XML 44 modular_3q23_htm.xml IDEA: XBRL DOCUMENT 0001074871 2022-04-01 2022-12-31 0001074871 2023-02-08 0001074871 2022-12-31 0001074871 2022-03-31 0001074871 2022-10-01 2022-12-31 0001074871 2021-10-01 2021-12-31 0001074871 2021-04-01 2021-12-31 0001074871 us-gaap:CommonStockMember 2022-03-31 0001074871 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001074871 modd:CommonStockIssuableMember 2022-03-31 0001074871 us-gaap:RetainedEarningsMember 2022-03-31 0001074871 us-gaap:CommonStockMember 2021-03-31 0001074871 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001074871 modd:CommonStockIssuableMember 2021-03-31 0001074871 us-gaap:RetainedEarningsMember 2021-03-31 0001074871 2021-03-31 0001074871 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001074871 modd:CommonStockIssuableMember 2022-04-01 2022-06-30 0001074871 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001074871 2022-04-01 2022-06-30 0001074871 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001074871 modd:CommonStockIssuableMember 2022-07-01 2022-09-30 0001074871 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001074871 2022-07-01 2022-09-30 0001074871 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001074871 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001074871 modd:CommonStockIssuableMember 2022-10-01 2022-12-31 0001074871 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001074871 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001074871 modd:CommonStockIssuableMember 2021-04-01 2021-06-30 0001074871 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001074871 2021-04-01 2021-06-30 0001074871 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001074871 modd:CommonStockIssuableMember 2021-07-01 2021-09-30 0001074871 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001074871 2021-07-01 2021-09-30 0001074871 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001074871 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001074871 modd:CommonStockIssuableMember 2021-10-01 2021-12-31 0001074871 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001074871 us-gaap:CommonStockMember 2022-06-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001074871 modd:CommonStockIssuableMember 2022-06-30 0001074871 us-gaap:RetainedEarningsMember 2022-06-30 0001074871 2022-06-30 0001074871 us-gaap:CommonStockMember 2022-09-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001074871 modd:CommonStockIssuableMember 2022-09-30 0001074871 us-gaap:RetainedEarningsMember 2022-09-30 0001074871 2022-09-30 0001074871 us-gaap:CommonStockMember 2022-12-31 0001074871 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001074871 modd:CommonStockIssuableMember 2022-12-31 0001074871 us-gaap:RetainedEarningsMember 2022-12-31 0001074871 us-gaap:CommonStockMember 2021-06-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001074871 modd:CommonStockIssuableMember 2021-06-30 0001074871 us-gaap:RetainedEarningsMember 2021-06-30 0001074871 2021-06-30 0001074871 us-gaap:CommonStockMember 2021-09-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001074871 modd:CommonStockIssuableMember 2021-09-30 0001074871 us-gaap:RetainedEarningsMember 2021-09-30 0001074871 2021-09-30 0001074871 us-gaap:CommonStockMember 2021-12-31 0001074871 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001074871 modd:CommonStockIssuableMember 2021-12-31 0001074871 us-gaap:RetainedEarningsMember 2021-12-31 0001074871 2021-12-31 0001074871 2021-11-24 2021-11-24 0001074871 2020-04-24 0001074871 us-gaap:ConvertibleNotesPayableMember 2021-04-30 0001074871 2021-04-01 2021-04-30 0001074871 us-gaap:ConvertibleNotesPayableMember 2021-05-31 0001074871 us-gaap:WarrantMember 2021-04-01 2021-12-31 0001074871 modd:Warrant1Member 2022-12-31 0001074871 modd:Warrant2Member 2022-12-31 0001074871 modd:Warrant3Member 2022-12-31 0001074871 modd:Warrant4Member 2022-12-31 0001074871 2017-10-01 2017-10-31 0001074871 2020-01-31 0001074871 2021-08-31 0001074871 srt:MinimumMember 2022-10-01 2022-12-31 0001074871 srt:MaximumMember 2022-10-01 2022-12-31 0001074871 srt:MinimumMember 2021-10-01 2021-12-31 0001074871 srt:MaximumMember 2021-10-01 2021-12-31 0001074871 srt:MinimumMember 2022-04-01 2022-12-31 0001074871 srt:MaximumMember 2022-04-01 2022-12-31 0001074871 srt:MinimumMember 2021-04-01 2021-12-31 0001074871 srt:MaximumMember 2021-04-01 2021-12-31 0001074871 us-gaap:StockOptionMember 2022-03-31 0001074871 us-gaap:StockOptionMember 2022-04-01 2022-06-30 0001074871 us-gaap:StockOptionMember 2022-06-30 0001074871 us-gaap:StockOptionMember 2022-07-01 2022-09-30 0001074871 us-gaap:StockOptionMember 2022-09-30 0001074871 us-gaap:StockOptionMember 2022-10-01 2022-12-31 0001074871 us-gaap:StockOptionMember 2022-12-31 0001074871 srt:MinimumMember us-gaap:StockOptionMember 2022-12-31 0001074871 srt:MaximumMember us-gaap:StockOptionMember 2022-12-31 0001074871 us-gaap:SubsequentEventMember 2023-01-01 2023-01-31 iso4217:USD shares iso4217:USD shares pure 0001074871 false --03-31 2023 Q3

P5Y9M

P5Y

P5Y8M12D

P5Y

P6Y

P5Y

P5Y8M12D

P5Y

P6Y2M12D

P7Y11M8D

10-Q true 2022-12-31 false 001-41277 MODULAR MEDICAL, INC. NV 87-0620495 16772 W. Bernardo Drive San Diego CA 92127 (858) 800-3500 Common Stock, par value $0.001 per share MODD NASDAQ Yes Yes Non-accelerated Filer true true false false 10932098

7690957

9076372

180164

313422

100000

7971121

9389794

716409

235959

51312

120693

100000

767721

456652

8738842

9846446

382080

299951

255545

524891

77672

144857

715297

969699

39957

715297

1009656

0.001

5000000

0.001

50000000

10932098

10461898

10932

10462

52900066

43406099

-44887453

-34579771

8023545

8836790

8738842

9846446

2196546

1849399

6804069

5742911

1161351

1981665

3502029

5156152

3357897

3831064

10306098

10899063

-3357897

-3831064

-10306098

-10899063

-587

368876

1010247

2204917

-1321450

-3358484

-4841307

-10306082

-14056554

1600

-3358484

-4841307

-10307682

-14058154

-0.31 -0.76 -0.95 -2.22 10925862 6354145 10863082 6331982

10461898

10462

43406099

-34579771

8836790

348

1576

449438 449 7371898 7372347

2664

13747

13750

724819

-3498791

10914348

10914

51518139

-38078562

13450491

11375

50368

50380

692060

-3450407

10925723

10926

52260567

-41528969

10742524

6375

12737

12743

626762

-3358484

10932098

10932

52900066

-44887453

8023545

6302050

6302

14665559

-15947010

-1275149

20000

172180

172200

3700632

1836

32495

32497

623423

-4835091

6323886

6324

19194289

-20782101

-1581488

3635

862427

862431

-4381757

6327521

6328

20056716

-25163858

-5100814

30865

249969

250000

8334

73748

73756

149994 149994

1211

1 1

5775

1221729

1221735

-4841307

6373706

6374

21602162

149994

-30005165

-8246635

-10307682

-14058154

-368780

-1321450

2120513

2740086

92616

80268

150412

388021

149994

69381

58404

-107142 -92826

1454762

-15577

-25995

-187217

1223983

-8184696

-7128787

573066

22779

-573066

-22779

7372347

250000

4137199

1500000

7372347

5887199

-1385415

-1264367

9076372

1468465

7690957

204098

3700632

<p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zec4kiJFWWl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">NOTE 1 – THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Modular Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras acquired in the merger at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc. The Company is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps for insulin-dependent people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent diabetes to receive their daily insulin in two ways, through a continuous “basal” delivery allowing a small amount of insulin to be in the blood at all times and a “bolus” delivery to address meal time glucose input and to address when the blood glucose level becomes excessively high. By addressing the time and effort required to effectively treat their condition, the Company believes it can address the less technically savvy, less motivated part of the market. In February 2022, the Company completed a public offering of its equity securities, and its common stock was approved to list on the Nasdaq Capital Market under the symbol “MODD” and began trading there on February 10, 2022. Liquidity Financial Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15), Going Concern, requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. If management identifies conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern, management must consider if there are plans that are probable to be implemented, and whether it is probable that the plans will mitigate the conditions or events raising the substantial doubt about the entity’s ability to continue as a going concern. If the substantial doubt is not alleviated after consideration of management’s plans, the entity must include a statement in the notes to the financial statements indicating that there is substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued including: 1) the principal conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, 2) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, and 3) management’s plans to attempt to mitigate the conditions or events causing the substantial doubt about the entity’s ability to continue as a going concern. The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. The Company’s expected operating losses and cash burn raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. The Company’s operating needs include the planned costs to operate its business, fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty. Basis of Presentation The Company’s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2023 refers to the fiscal year ending March 31, 2023). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and with the rules and regulations of the United States Security and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated balance sheet as of March 31, 2022 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with these rules and regulations of the SEC. The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three months ended December 31, 2022 are not necessarily indicative of the results that may be expected for the year ending March 31, 2023 or for any other future period. Reverse Stock Split On November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company’s shares of common stock. Such amendment and ratio were previously approved by a majority of the Company’s stockholders and the board of directors. As a result of the reverse stock split, which was effective November 29, 2021, every three shares of the Company’s pre-reverse split outstanding common stock were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stock holders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the reverse split were rounded up to the nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company’s equity incentive plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split. All share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3 reverse stock split. Use of Estimates The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates. Reportable Segment The Company operates in one business segment and uses one measurement of profitability for its business. Research and Development The Company expenses research and development expenditures as incurred. General and Administrative General and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees, and office and other administrative expenses. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure. Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets. The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in- place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. Property and Equipment Property and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended use. Fixed assets comprised: Schedule of Fixed Assets <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_zG9xGF5lWi7" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td colspan="2" id="xdx_49A_20221231_zmWLzapN6Bqa" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td colspan="2" id="xdx_490_20220331_zgvFociyeck6" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--MachineryAndEquipmentGross_iI_maPPAEGzm0x_zek7E3B1Okmg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Machinery and equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">487,855</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">346,358</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConstructionInProgressGross_iI_maPPAEGzm0x_zLH4nMyJKHJ" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Construction-in-process</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">427,670</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseholdImprovementsGross_iI_maPPAEGzm0x_z9C4hqtLdnk6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">139,197</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">139,197</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGzm0x_maPPAENzKLp_zwgY5bqSSMR7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Total property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,054,722</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">485,555</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzKLp_zgWjSeb7oXxd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(338,313</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(249,596</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzKLp_z3bXSX4Jcb54" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt; padding-bottom: 2.5pt">Total property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">716,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">235,959</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> Fair Value of Financial Instruments The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 9.85pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 43.95pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt">·</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 1.25pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 43.95pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt">·</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 1.6pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 43.95pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt">·</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</td></tr></table> Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value. Right-of-Use Asset The Company’s right-of-use assets consist of leased assets recognized in accordance with FASB Accounting Standards Codification (ASC) No. 842, Leases which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the condensed consolidated balance sheets and are expensed on a straight-line basis over the lease term in the condensed consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Stock-Based Compensation The Company recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and projected stock option exercise behaviors. Per-Share Amounts Basic net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and warrants. <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z7O4MGwvLHa1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">For the nine months ended December 31, 2022 and 2021, the following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive. Schedule of Anti-Dilutive Shares <table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails2Abstract_zc6OdvANtPEi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"/><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"/> <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td id="xdx_493_20220401__20221231_zg7tRAEeeDFb" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td id="xdx_491_20210401__20211231_zAdb6qE31bK7" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"/></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Nine Months Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_zzezQ1keKJ6j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left">Options to purchase common stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">2,174,198</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">1,967,188</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_zU4c4j6hnLm" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Common stock warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,565,588</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">767,796</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zuvQIw0fl2Y1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 8.65pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,739,786</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,734,984</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and nine months ended December 31, 2022 and 2021, the Company’s comprehensive loss was the same as its net loss. Recently Issued Accounting Pronouncement In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses. This ASU added a new impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes an allowance for its estimate of expected credit losses and applies to most debt instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that have a low risk of loss. This update is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years for smaller reporting companies. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations and financial position.

Liquidity Financial Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15), Going Concern, requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. If management identifies conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern, management must consider if there are plans that are probable to be implemented, and whether it is probable that the plans will mitigate the conditions or events raising the substantial doubt about the entity’s ability to continue as a going concern. If the substantial doubt is not alleviated after consideration of management’s plans, the entity must include a statement in the notes to the financial statements indicating that there is substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued including: 1) the principal conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, 2) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, and 3) management’s plans to attempt to mitigate the conditions or events causing the substantial doubt about the entity’s ability to continue as a going concern. The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. The Company’s expected operating losses and cash burn raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. The Company’s operating needs include the planned costs to operate its business, fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty.

Basis of Presentation The Company’s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2023 refers to the fiscal year ending March 31, 2023). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and with the rules and regulations of the United States Security and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated balance sheet as of March 31, 2022 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with these rules and regulations of the SEC. The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three months ended December 31, 2022 are not necessarily indicative of the results that may be expected for the year ending March 31, 2023 or for any other future period.

Reverse Stock Split On November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company’s shares of common stock. Such amendment and ratio were previously approved by a majority of the Company’s stockholders and the board of directors. As a result of the reverse stock split, which was effective November 29, 2021, every three shares of the Company’s pre-reverse split outstanding common stock were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stock holders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the reverse split were rounded up to the nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company’s equity incentive plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split. All share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3 reverse stock split.

Use of Estimates The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.

Reportable Segment The Company operates in one business segment and uses one measurement of profitability for its business.

Research and Development The Company expenses research and development expenditures as incurred.

General and Administrative General and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees, and office and other administrative expenses.

Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure.

Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets. The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in- place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted.

Cash and Cash Equivalents Cash and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.

Property and Equipment Property and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended use. Fixed assets comprised: Schedule of Fixed Assets <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_zG9xGF5lWi7" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td colspan="2" id="xdx_49A_20221231_zmWLzapN6Bqa" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td colspan="2" id="xdx_490_20220331_zgvFociyeck6" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--MachineryAndEquipmentGross_iI_maPPAEGzm0x_zek7E3B1Okmg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Machinery and equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">487,855</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">346,358</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConstructionInProgressGross_iI_maPPAEGzm0x_zLH4nMyJKHJ" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Construction-in-process</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">427,670</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseholdImprovementsGross_iI_maPPAEGzm0x_z9C4hqtLdnk6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">139,197</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">139,197</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGzm0x_maPPAENzKLp_zwgY5bqSSMR7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Total property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,054,722</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">485,555</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzKLp_zgWjSeb7oXxd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(338,313</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(249,596</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzKLp_z3bXSX4Jcb54" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt; padding-bottom: 2.5pt">Total property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">716,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">235,959</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

Fixed assets comprised: Schedule of Fixed Assets

<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_zG9xGF5lWi7" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td colspan="2" id="xdx_49A_20221231_zmWLzapN6Bqa" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td colspan="2" id="xdx_490_20220331_zgvFociyeck6" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--MachineryAndEquipmentGross_iI_maPPAEGzm0x_zek7E3B1Okmg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Machinery and equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">487,855</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">346,358</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConstructionInProgressGross_iI_maPPAEGzm0x_zLH4nMyJKHJ" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Construction-in-process</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">427,670</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseholdImprovementsGross_iI_maPPAEGzm0x_z9C4hqtLdnk6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">139,197</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">139,197</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGzm0x_maPPAENzKLp_zwgY5bqSSMR7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Total property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,054,722</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">485,555</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzKLp_zgWjSeb7oXxd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(338,313</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(249,596</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzKLp_z3bXSX4Jcb54" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt; padding-bottom: 2.5pt">Total property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">716,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">235,959</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

487855

346358

427670

139197

1054722

485555

338313

249596

716409

235959

Fair Value of Financial Instruments The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 9.85pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 43.95pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt">·</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 1.25pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 43.95pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt">·</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 1.6pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 43.95pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt">·</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</td></tr></table> Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.

Right-of-Use Asset The Company’s right-of-use assets consist of leased assets recognized in accordance with FASB Accounting Standards Codification (ASC) No. 842, Leases which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the condensed consolidated balance sheets and are expensed on a straight-line basis over the lease term in the condensed consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.

Stock-Based Compensation The Company recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and projected stock option exercise behaviors.

Per-Share Amounts Basic net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and warrants. <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z7O4MGwvLHa1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">For the nine months ended December 31, 2022 and 2021, the following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive. Schedule of Anti-Dilutive Shares <table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails2Abstract_zc6OdvANtPEi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"/><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"/> <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td id="xdx_493_20220401__20221231_zg7tRAEeeDFb" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td id="xdx_491_20210401__20211231_zAdb6qE31bK7" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"/></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Nine Months Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_zzezQ1keKJ6j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left">Options to purchase common stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">2,174,198</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">1,967,188</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_zU4c4j6hnLm" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Common stock warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,565,588</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">767,796</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zuvQIw0fl2Y1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 8.65pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,739,786</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,734,984</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

<p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z7O4MGwvLHa1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">For the nine months ended December 31, 2022 and 2021, the following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive. Schedule of Anti-Dilutive Shares

<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails2Abstract_zc6OdvANtPEi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"/><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"/> <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td id="xdx_493_20220401__20221231_zg7tRAEeeDFb" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/> <td id="xdx_491_20210401__20211231_zAdb6qE31bK7" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"/><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"/></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Nine Months Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_zzezQ1keKJ6j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left">Options to purchase common stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">2,174,198</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">1,967,188</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_zU4c4j6hnLm" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Common stock warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,565,588</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">767,796</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zuvQIw0fl2Y1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 8.65pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,739,786</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,734,984</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

2174198

1967188

7565588

767796

9739786

2734984

Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.

Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and nine months ended December 31, 2022 and 2021, the Company’s comprehensive loss was the same as its net loss.

Recently Issued Accounting Pronouncement In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses. This ASU added a new impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes an allowance for its estimate of expected credit losses and applies to most debt instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that have a low risk of loss. This update is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years for smaller reporting companies. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations and financial position.

NOTE 2 – LEASES The Company accounts for the lease of its corporate facility in San Diego, California in accordance with ASC No. 842. The 39- month lease term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $12,400 with annual rent increases of approximately 3%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. The right-to-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease payments. A discount rate of 11%, which approximated the Company’s incremental borrowing rate, was used to measure the lease asset and liability. Lease expense is recognized on a straight-line basis over the lease term. The Company obtained a right-of-use asset of $270,950 in exchange for its obligations under the operating lease. The landlord also provided a lease incentive of approximately $139,000, which was paid to the Company in June 2020, for the Company to make improvements to the leased space. In addition, the Company paid a $100,000 security deposit. <p id="xdx_89B_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_z0dprAtKHKW" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">Future minimum payments under the facility operating lease, as of December 31, 2022, are listed in the table below. Schedule of Future minimum Lease Payment <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureLeasesDetailsAbstract_z3CS1aSTeSs3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Annual Fiscal Years</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20221231_zQmRulKPyczi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Operating Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz3Dp_zHRCkxRdrGt4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 87%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">39,507</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_maOLFMPz3Dp_zVwPIbUWzwa9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">40,692</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Less:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingLeasesImputedInterest_iI_maOLFMPz3Dp_zeF3c8SkkG7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,527</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_mtOLFMPz3Dp_z8vWATFqUgm4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Present value of lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">77,672</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> Cash paid for amounts included in the measurement of lease liabilities was $118,521 for the nine months ended December 31, 2022. Rent expense was $80,698 for each of the nine-month periods ended December 31, 2022 and 2021 and $26,930 for each of the three-month periods ended December 31, 2022 and 2021.

<p id="xdx_89B_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_z0dprAtKHKW" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">Future minimum payments under the facility operating lease, as of December 31, 2022, are listed in the table below. Schedule of Future minimum Lease Payment

<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureLeasesDetailsAbstract_z3CS1aSTeSs3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Annual Fiscal Years</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20221231_zQmRulKPyczi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Operating Lease</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz3Dp_zHRCkxRdrGt4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 87%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">39,507</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_maOLFMPz3Dp_zVwPIbUWzwa9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">40,692</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Less:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingLeasesImputedInterest_iI_maOLFMPz3Dp_zeF3c8SkkG7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,527</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_mtOLFMPz3Dp_z8vWATFqUgm4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Present value of lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">77,672</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

39507

40692

-2527

77672

118521

80698

26930

NOTE 3 – PPP NOTE On April 24, 2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was established under the U.S. government’s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note. The full amount of the PPP Note was due in April 2022 and interest accrued on the outstanding principal balance of the PPP Note at a fixed rate of 1.0% per annum, which was deferred for 10 months after the covered period during which the Company used the proceeds. In May 2021, the Lender and the U.S. Small Business Administration notified the Company that the outstanding principal and accrued interest for the PPP Note was forgiven in full. The Company accounted for the forgiveness of the PPP Note in accordance with ASC Topic 470: Debt (ASC 470), and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the consolidated statement of operations.

368780

NOTE 4 – CONVERTIBLE PROMISSORY NOTES From February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Note and, collectively, the Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between each holder of an Original Note and the Company, the $2,310,000 of Original Notes and accrued interest thereon as of April 30, 2021 were replaced with $2,360,550 aggregate principal amount of Notes and 2021 Warrants (as defined below). The Company accounted for the replacement of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $1,321,450 and interest expense of $70,647 for unamortized debt issuance costs as of April 30, 2021. In April and May 2021, pursuant to a securities purchase agreement by and between the Company and each investor (the SPA), the Company sold to investors $4,250,000 aggregate principal amount of convertible promissory notes (the Notes) and warrants to purchase shares of its common stock (the 2021 Warrants). The Notes were unsecured obligations of the Company with each Note having a stated maturity date of 12 months from its issue date and accrued interest at a rate of 12% per annum, payable on maturity. If the Company completed an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise, as defined in the Notes), each Note holder would be required to convert its Adjusted Note Amount (as defined below) into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued interest on a Note, multiplied by (ii) 1.25. In connection with the issuance of the Notes, the Company issued the 2021 Warrants to purchase in the aggregate 767,796 shares of its common stock at an initial exercise price of $24.00 per share. The fair value of the 2021 Warrants was $3,700,632, of which $2,379,182 was recorded as a debt discount and amortized to interest expense, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated the fair value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_c20210401__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbJ6jH4tPNhc">88.98%, risk-free interest rate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCIGxw5MoXO4">0.86%, a term of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN6AMLkZFgN3" title="::XDX::P5Y9M">5.75 years and a dividend yield of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dc_c20210401__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkIAKgIzLdV6">zero. Upon the closing of a public offering in February 2022, which was a Qualified Capital Raise, in accordance with their terms, the Notes converted into 1,511,276 shares of common stock and the holders of the Notes received an additional 1,511,276 common stock purchase warrants with an exercise price of $6.60 per share. In addition, as a result of the February 2022 equity offering, the exercise price of the 767,796 outstanding 2021 Warrants was reduced to $6.00 per share.

2310000

-1321450

70647

4250000

0.8898

0.0086

NOTE 5 – STOCKHOLDERS’ EQUITY (DEFICIT) Placements of Common Stock and Warrants On May 2, 2022, the Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor, pursuant to which the Company sold, in a registered direct offering (the Registered Offering), which closed on May 5, 2022, an aggregate of 449,438 shares (the Shares) of the Company’s common stock, par value $0.001 per share, at a purchase price per Share of $4.45 and pre-funded warrants (the Pre-Funded Warrants) to purchase an aggregate of 1,348,314 shares of common stock at a purchase price per Pre-Funded Warrant of $4.44. The Pre-Funded Warrants will be exercisable immediately on the date of issuance at an exercise price of $0.01 per share and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. In a concurrent private placement under the Purchase Agreement, the Company issued to the Investor warrants (the Private Placement Warrants) to purchase an aggregate of 1,438,202 shares of common stock at an exercise price of $6.60 per share. The Private Placement Warrants will be exercisable beginning on the six-month anniversary of the date of issuance (the Initial Exercise Date) and will expire on the five-year anniversary of the Initial Exercise Date. Warrants As of December 31, 2022, the Company had the following warrants outstanding: Schedule of Warrant Outstanding <table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureStockholdersEquityDeficitDetailsAbstract_zjj4p29K9gSa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> Type</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_485_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_zLAQtgeJQFI4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_48D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_zN8oCISN6Zo9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Expiration Date</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr id="xdx_413_20221231__us-gaap--StatementEquityComponentsAxis__custom--Warrant1Member_zmiECoOFcbXa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Common stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">1,348,314</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_41B_20221231__us-gaap--StatementEquityComponentsAxis__custom--Warrant2Member_zGjfaW0vLyVd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Common stock</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">767,796</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">January - February 2027</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_41D_20221231__us-gaap--StatementEquityComponentsAxis__custom--Warrant3Member_zh47qkMAGOR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Common stock</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,011,276</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.60</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">February 2027</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_41B_20221231__us-gaap--StatementEquityComponentsAxis__custom--Warrant4Member_zBG2m10V9iNi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Common stock</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,438,202</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">6.60</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: right">November 2027</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_418_20221231_zXWCK824esri" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -8.65pt; padding-left: 17.3pt; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,565,588</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 2.5pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Other During the nine months ended December 31, 2022 and 2021, the Company issued 348 and 28,334 shares of common stock, respectively, with a fair value of approximately $1,576 and $245,956, respectively, to service providers.

As of December 31, 2022, the Company had the following warrants outstanding: Schedule of Warrant Outstanding

<table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureStockholdersEquityDeficitDetailsAbstract_zjj4p29K9gSa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> Type</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_485_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_zLAQtgeJQFI4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_48D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_zN8oCISN6Zo9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Expiration Date</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr id="xdx_413_20221231__us-gaap--StatementEquityComponentsAxis__custom--Warrant1Member_zmiECoOFcbXa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Common stock</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">1,348,314</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_41B_20221231__us-gaap--StatementEquityComponentsAxis__custom--Warrant2Member_zGjfaW0vLyVd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Common stock</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">767,796</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">January - February 2027</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_41D_20221231__us-gaap--StatementEquityComponentsAxis__custom--Warrant3Member_zh47qkMAGOR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Common stock</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,011,276</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.60</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">February 2027</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_41B_20221231__us-gaap--StatementEquityComponentsAxis__custom--Warrant4Member_zBG2m10V9iNi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Common stock</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,438,202</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">6.60</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: right">November 2027</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_418_20221231_zXWCK824esri" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -8.65pt; padding-left: 17.3pt; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,565,588</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 2.5pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1348314

0.01

767796

6.00

4011276

6.60

1438202

6.60

7565588

348

28334

1576

245956

NOTE 6 – STOCK-BASED COMPENSATION Amended 2017 Equity Incentive Plan In October 2017, the Company’s board of directors (the Board) approved the 2017 Equity Incentive Plan (the Plan), as amended, with 1,000,000 shares of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance under the Plan by 333,334 and 1,333,334 shares, respectively. Under the Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board. Stock-Based Compensation Expense The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant date fair value. As of December 31, 2022, the unamortized compensation cost was $3,443,902 related to stock options and is expected to be recognized as expense over a weighted-average period of approximately 2.07 years. During the three and nine months ended December 31, 2022, the Company awarded 6,375 and 20,414 shares, respectively, to members of the Board in accordance with the compensation plan for non-employee directors. During the nine months ended December 31, 2022, the Company granted options with 10-year terms to purchase 677,199 shares of its common stock to employees, directors and consultants. The fair value of the options granted and shares awarded was $2,503,979. The following assumptions were used in the fair value calculations of the options granted: Schedule of Fair value Assumptions of Options <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zb2gfZU2Z0J1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Three Months Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Nine Months Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2022</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2022</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Risk-free interest rates</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">3.93% - 3.99%</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">1.26% - 1.36%</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">2.82% - 4.06%</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0.8% - 1.36%</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; padding-left: 8.65pt; text-indent: -8.65pt">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">149%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">197% - 253%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">149% - 223%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">89% - 370%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Expected life (years)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20221001__20221231__srt--RangeAxis__srt--MinimumMember_zWiB2RLckmS9" title="::XDX::P5Y">5.0 - <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20221001__20221231__srt--RangeAxis__srt--MaximumMember_zP1GEN0yPMgf" title="::XDX::P5Y8M12D">5.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zYkx3rVLRkCg" title="::XDX::P5Y">5.0 - <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zzPpmaLjGlzk" title="::XDX::P6Y">6.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20220401__20221231__srt--RangeAxis__srt--MinimumMember_zUbR0lrpP2Ib" title="::XDX::P5Y">5.0 - <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20220401__20221231__srt--RangeAxis__srt--MaximumMember_zLiz3M5ZWXob" title="::XDX::P5Y8M12D">5.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zD0iKBsDmqxj" title="::XDX::P5Y">5.0 - <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zF8sMY22DC08" title="::XDX::P6Y2M12D">6.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options, as well as average volatility. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. A summary of stock option activity under the Plan is presented below: Schedule of Stock Option activity <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zZEUT7iODGri" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Options Outstanding</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Shares Available for Grant</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Weighted Average Exercise Prices</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 61%; padding-left: 8.65pt; text-indent: -8.65pt">Balance at March 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDy2ZNa8cqj" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">989,466</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zey9NhNQqYKl" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">1,650,705</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzGjv2vDzmUj" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">6.58</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Options granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zt5cZC9tlNyi" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(265,634</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zF1lcx5rJ4Kf" style="font: 10pt Times New Roman, Times, Serif; text-align: right">265,634</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjXQ2jQ07gF2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.35</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt; text-indent: -8.65pt">Share awards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpG9RRJ1Ya5l" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,664</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt; padding-bottom: 1pt">Options cancelled and returned to the Plan</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVwUAvfqDHF8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">96,668</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfZyjahfONke" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(96,668</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7revZ6gLvo2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">7.69</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt">Balance at June 30, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKDI4Lq1Ao01" style="font: 10pt Times New Roman, Times, Serif; text-align: right">817,836</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zp1sb1DyW6L1" style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,819,671</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNhPwI6Rmdsd" style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.19</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Options granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBreamkFPmdg" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(241,023</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqiXTkYMtST6" style="font: 10pt Times New Roman, Times, Serif; text-align: right">241,023</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmmWWHda1HYf" style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.35</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt; text-indent: -8.65pt">Share awards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEgTeuBeqMu4" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(11,375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt; padding-bottom: 1pt">Options cancelled and returned to the Plan</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9DsRMechIu8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">30,444</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGLLZr5HK8Zk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(30,444</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zySAXxhq9Pq1" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">4.67</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt">Balance at September 30, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zr8Nt9rq5XLa" style="font: 10pt Times New Roman, Times, Serif; text-align: right">595,882</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z02kzxgfOHD9" style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,030,250</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z65KPeBi3ji9" style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Options granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHXwHpcx8WFa" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(170,542</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQUVYkx5GIpa" style="font: 10pt Times New Roman, Times, Serif; text-align: right">170,542</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVLIO2MKT468" style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt; text-indent: -8.65pt">Share awards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxp32JmLZqBh" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt; padding-bottom: 1pt">Options cancelled and returned to the Plan</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAtL26VmkYUg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">26,594</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdzv8WLSNNla" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(26,594</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzrdxN4arP6h" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">5.82</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zN3t4pRDkxBc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">445,559</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGorHuGaIhQg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,174,198</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZCjhztw4Zg5" style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.69</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> There were no stock options exercised during the nine months ended December 31, 2022 and 2021. <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zLTJSD7Iorei" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">The following table summarizes the range of outstanding and exercisable options as of December 31, 2022: Schedule of Outstanding and Exercisable Option, Range <table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zx6IDv9Up01c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 12pt; text-align: center; padding-bottom: 1pt"> </td><td style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Options Exercisable</td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number Outstanding</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number Exercisable</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center; text-indent: 8.65pt"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center; text-indent: 17.3pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate Intrinsic value</td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 22%; padding-bottom: 1pt">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zSSmqA688zcb">1.98 - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zYUI4ctrSybb">17.70</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9Y0X0GwqaPb" style="width: 8%; text-align: right; padding-bottom: 1pt">2,174,198</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1xwZAO3lb8l" style="width: 8%; text-align: right; padding-bottom: 1pt" title="::XDX::P7Y11M8D">7.94</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; padding-bottom: 1pt">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zA9fHg2sUkDl" style="width: 8%; text-align: right; padding-bottom: 1pt">5.69</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdX1z2gbABl2" style="width: 8%; text-align: right; padding-bottom: 1pt">1,360,318</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; padding-bottom: 1pt">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpPmoee7T7ee" style="width: 8%; text-align: right; padding-bottom: 1pt">5.87</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zomTXbehsQWk" style="width: 8%; text-align: right">8,894</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td></tr> </table> The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company’s principal trading market over the exercise price of the option. The Company is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise of stock options as financing cash flows in the consolidated statements of cash flows. For the nine months ended December 31, 2022 and 2021, there were no such tax benefits associated with the exercise of stock options, as no stock options were exercised.

1000000

333334

1333334

Schedule of Fair value Assumptions of Options

<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zb2gfZU2Z0J1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Three Months Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Nine Months Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2022</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2022</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Risk-free interest rates</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">3.93% - 3.99%</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">1.26% - 1.36%</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">2.82% - 4.06%</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0.8% - 1.36%</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; padding-left: 8.65pt; text-indent: -8.65pt">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">149%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">197% - 253%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">149% - 223%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">89% - 370%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Expected life (years)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20221001__20221231__srt--RangeAxis__srt--MinimumMember_zWiB2RLckmS9" title="::XDX::P5Y">5.0 - <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20221001__20221231__srt--RangeAxis__srt--MaximumMember_zP1GEN0yPMgf" title="::XDX::P5Y8M12D">5.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zYkx3rVLRkCg" title="::XDX::P5Y">5.0 - <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zzPpmaLjGlzk" title="::XDX::P6Y">6.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20220401__20221231__srt--RangeAxis__srt--MinimumMember_zUbR0lrpP2Ib" title="::XDX::P5Y">5.0 - <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20220401__20221231__srt--RangeAxis__srt--MaximumMember_zLiz3M5ZWXob" title="::XDX::P5Y8M12D">5.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zD0iKBsDmqxj" title="::XDX::P5Y">5.0 - <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zF8sMY22DC08" title="::XDX::P6Y2M12D">6.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

0.0393

0.0399

0.0126

0.0136

0.0282

0.0406

0.008

0.0136

1.49

1.97

2.53

1.49

2.23

0.89

3.70

A summary of stock option activity under the Plan is presented below: Schedule of Stock Option activity

<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zZEUT7iODGri" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Options Outstanding</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Shares Available for Grant</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Weighted Average Exercise Prices</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 61%; padding-left: 8.65pt; text-indent: -8.65pt">Balance at March 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDy2ZNa8cqj" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">989,466</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zey9NhNQqYKl" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">1,650,705</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzGjv2vDzmUj" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">6.58</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Options granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zt5cZC9tlNyi" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(265,634</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zF1lcx5rJ4Kf" style="font: 10pt Times New Roman, Times, Serif; text-align: right">265,634</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjXQ2jQ07gF2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.35</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt; text-indent: -8.65pt">Share awards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpG9RRJ1Ya5l" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,664</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt; padding-bottom: 1pt">Options cancelled and returned to the Plan</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVwUAvfqDHF8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">96,668</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfZyjahfONke" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(96,668</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7revZ6gLvo2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">7.69</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt">Balance at June 30, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKDI4Lq1Ao01" style="font: 10pt Times New Roman, Times, Serif; text-align: right">817,836</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zp1sb1DyW6L1" style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,819,671</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNhPwI6Rmdsd" style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.19</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Options granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBreamkFPmdg" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(241,023</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqiXTkYMtST6" style="font: 10pt Times New Roman, Times, Serif; text-align: right">241,023</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmmWWHda1HYf" style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.35</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt; text-indent: -8.65pt">Share awards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEgTeuBeqMu4" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(11,375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt; padding-bottom: 1pt">Options cancelled and returned to the Plan</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9DsRMechIu8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">30,444</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGLLZr5HK8Zk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(30,444</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zySAXxhq9Pq1" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">4.67</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt">Balance at September 30, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zr8Nt9rq5XLa" style="font: 10pt Times New Roman, Times, Serif; text-align: right">595,882</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z02kzxgfOHD9" style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,030,250</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z65KPeBi3ji9" style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Options granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHXwHpcx8WFa" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(170,542</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQUVYkx5GIpa" style="font: 10pt Times New Roman, Times, Serif; text-align: right">170,542</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVLIO2MKT468" style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt; text-indent: -8.65pt">Share awards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxp32JmLZqBh" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt; padding-bottom: 1pt">Options cancelled and returned to the Plan</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAtL26VmkYUg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">26,594</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdzv8WLSNNla" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(26,594</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzrdxN4arP6h" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">5.82</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zN3t4pRDkxBc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">445,559</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGorHuGaIhQg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,174,198</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZCjhztw4Zg5" style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.69</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

989466

1650705

6.58

-265634

265634

4.35

-2664 96668

96668

7.69

817836

1819671

6.19

-241023

241023

4.35

-11375 30444

30444

4.67

595882

2030250

6.00

-170542

170542

2.00

-6375 26594

26594

5.82

445559

2174198

5.69

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zLTJSD7Iorei" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">The following table summarizes the range of outstanding and exercisable options as of December 31, 2022: Schedule of Outstanding and Exercisable Option, Range

<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zx6IDv9Up01c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 12pt; text-align: center; padding-bottom: 1pt"> </td><td style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Options Exercisable</td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number Outstanding</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number Exercisable</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center; text-indent: 8.65pt"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center; text-indent: 17.3pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate Intrinsic value</td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 22%; padding-bottom: 1pt">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zSSmqA688zcb">1.98 - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zYUI4ctrSybb">17.70</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9Y0X0GwqaPb" style="width: 8%; text-align: right; padding-bottom: 1pt">2,174,198</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20221001__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1xwZAO3lb8l" style="width: 8%; text-align: right; padding-bottom: 1pt" title="::XDX::P7Y11M8D">7.94</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; padding-bottom: 1pt">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zA9fHg2sUkDl" style="width: 8%; text-align: right; padding-bottom: 1pt">5.69</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdX1z2gbABl2" style="width: 8%; text-align: right; padding-bottom: 1pt">1,360,318</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; padding-bottom: 1pt">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zpPmoee7T7ee" style="width: 8%; text-align: right; padding-bottom: 1pt">5.87</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zomTXbehsQWk" style="width: 8%; text-align: right">8,894</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td></tr> </table>

1.98

17.70

2174198

5.69

1360318

5.87

8894

NOTE 7 – INCOME TAXES The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance. The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns for fiscal 2016 to fiscal 2022 may be subject to examination by the U.S. federal and state tax authorities. As of December 31, 2022, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.

NOTE 8 – COMMITMENTS & CONTINGENCIES Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Indemnification In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company’s consolidated financial statements for the nine months ended December 31, 2022 and 2021 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements, and no claims for payment have been made under such agreements. Purchase Obligations The Company's primary purchase obligations include purchase orders for machinery and equipment. At December 31, 2022, the Company had outstanding purchase orders for machinery and equipment and related expenditures of approximately $735,000.

NOTE 9 – SUBSEQUENT EVENTS New Lease Agreement On January 5, 2023, the Company entered into a lease agreement (the Thornhill Lease) with Michael Summers (the Lessor) for a new headquarters facility pursuant to which the Company will lease approximately 24,000 square feet of a building located in San Diego, California, commencing on or about February 1, 2023. The monthly base rent is $36,000 for the first 12 months of the lease and will increase by 4% of the prior year’s base rent at the beginning of each 12-month period thereafter. The lease term is 48 months. Under the Thornhill Lease, the Company will pay the Lessor a monthly fee for its pro-rated share of specified common area charges, including maintenance costs, property taxes and insurance, in addition to base rent. The monthly fee for the common area charges is approximately $10,700 and will be adjusted based on actual costs incurred by the Lessor. Amended 2017 Equity Incentive Plan In January 2023, the Company’s stockholders approved an increase in the number of shares reserved for issuance under the Plan by <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_c20230101__20230131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znvywmqQW0O7" title="Shares approved under Equity Incentive Plan">2,000,000 shares.

2000000

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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r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end XML 46 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 104 184 1 false 14 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://modular-medical.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://modular-medical.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://modular-medical.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://modular-medical.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://modular-medical.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 00000008 - Disclosure - LEASES Sheet http://modular-medical.com/role/Leases LEASES Notes 8 false false R9.htm 00000009 - Disclosure - PPP NOTE Sheet http://modular-medical.com/role/PppNote PPP NOTE Notes 9 false false R10.htm 00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES Notes http://modular-medical.com/role/ConvertiblePromissoryNotes CONVERTIBLE PROMISSORY NOTES Notes 10 false false R11.htm 00000011 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) Sheet http://modular-medical.com/role/StockholdersEquityDeficit STOCKHOLDERS??? EQUITY (DEFICIT) Notes 11 false false R12.htm 00000012 - Disclosure - STOCK-BASED COMPENSATION Sheet http://modular-medical.com/role/Stock-basedCompensation STOCK-BASED COMPENSATION Notes 12 false false R13.htm 00000013 - Disclosure - INCOME TAXES Sheet http://modular-medical.com/role/IncomeTaxes INCOME TAXES Notes 13 false false R14.htm 00000014 - Disclosure - COMMITMENTS & CONTINGENCIES Sheet http://modular-medical.com/role/CommitmentsContingencies COMMITMENTS & CONTINGENCIES Notes 14 false false R15.htm 00000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://modular-medical.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 00000016 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 00000017 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - LEASES (Tables) Sheet http://modular-medical.com/role/LeasesTables LEASES (Tables) Tables http://modular-medical.com/role/Leases 18 false false R19.htm 00000019 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Tables) Sheet http://modular-medical.com/role/StockholdersEquityDeficitTables STOCKHOLDERS??? EQUITY (DEFICIT) (Tables) Tables http://modular-medical.com/role/StockholdersEquityDeficit 19 false false R20.htm 00000020 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://modular-medical.com/role/Stock-basedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://modular-medical.com/role/Stock-basedCompensation 20 false false R21.htm 00000021 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 00000022 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) Sheet http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails2 THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) Details http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 00000023 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 00000024 - Disclosure - LEASES (Details) Sheet http://modular-medical.com/role/LeasesDetails LEASES (Details) Details http://modular-medical.com/role/LeasesTables 24 false false R25.htm 00000025 - Disclosure - LEASES (Details Narrative) Sheet http://modular-medical.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://modular-medical.com/role/LeasesTables 25 false false R26.htm 00000026 - Disclosure - PPP NOTE (Details Narrative) Sheet http://modular-medical.com/role/PppNoteDetailsNarrative PPP NOTE (Details Narrative) Details http://modular-medical.com/role/PppNote 26 false false R27.htm 00000027 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative) Notes http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative CONVERTIBLE PROMISSORY NOTES (Details Narrative) Details http://modular-medical.com/role/ConvertiblePromissoryNotes 27 false false R28.htm 00000028 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details) Sheet http://modular-medical.com/role/StockholdersEquityDeficitDetails STOCKHOLDERS' EQUITY (DEFICIT) (Details) Details 28 false false R29.htm 00000029 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Details Narrative) Sheet http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative STOCKHOLDERS??? EQUITY (DEFICIT) (Details Narrative) Details http://modular-medical.com/role/StockholdersEquityDeficitTables 29 false false R30.htm 00000030 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://modular-medical.com/role/Stock-basedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://modular-medical.com/role/Stock-basedCompensationTables 30 false false R31.htm 00000031 - Disclosure - STOCK-BASED COMPENSATION (Details 2) Sheet http://modular-medical.com/role/Stock-basedCompensationDetails2 STOCK-BASED COMPENSATION (Details 2) Details http://modular-medical.com/role/Stock-basedCompensationTables 31 false false R32.htm 00000032 - Disclosure - STOCK-BASED COMPENSATION (Details 3) Sheet http://modular-medical.com/role/Stock-basedCompensationDetails3 STOCK-BASED COMPENSATION (Details 3) Details http://modular-medical.com/role/Stock-basedCompensationTables 32 false false R33.htm 00000033 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://modular-medical.com/role/Stock-basedCompensationTables 33 false false R34.htm 00000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://modular-medical.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://modular-medical.com/role/SubsequentEvents 34 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 10 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 - modular_3q23.htm 119, 120, 121, 122, 123, 124, 125, 126, 127, 128 modular_3q23.htm ex31_1.htm ex31_2.htm ex32_1.htm modd-20221231.xsd modd-20221231_cal.xml modd-20221231_def.xml modd-20221231_lab.xml modd-20221231_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 51 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "modular_3q23.htm": { "axisCustom": 0, "axisStandard": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 437, "http://xbrl.sec.gov/dei/2022": 30 }, "contextCount": 104, "dts": { "calculationLink": { "local": [ "modd-20221231_cal.xml" ] }, "definitionLink": { "local": [ "modd-20221231_def.xml" ] }, "inline": { "local": [ "modular_3q23.htm" ] }, "labelLink": { "local": [ "modd-20221231_lab.xml" ] }, "presentationLink": { "local": [ "modd-20221231_pre.xml" ] }, "schema": { "local": [ "modd-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 275, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 89, "http://modular-medical.com/20221231": 12, "http://xbrl.sec.gov/dei/2022": 5, "total": 106 }, "keyCustom": 26, "keyStandard": 158, "memberCustom": 5, "memberStandard": 9, "nsprefix": "modd", "nsuri": "http://modular-medical.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://modular-medical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES", "menuCat": "Notes", "order": "10", "role": "http://modular-medical.com/role/ConvertiblePromissoryNotes", "shortName": "CONVERTIBLE PROMISSORY NOTES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "menuCat": "Notes", "order": "11", "role": "http://modular-medical.com/role/StockholdersEquityDeficit", "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - STOCK-BASED COMPENSATION", "menuCat": "Notes", "order": "12", "role": "http://modular-medical.com/role/Stock-basedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "13", "role": "http://modular-medical.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - COMMITMENTS & CONTINGENCIES", "menuCat": "Notes", "order": "14", "role": "http://modular-medical.com/role/CommitmentsContingencies", "shortName": "COMMITMENTS & CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "15", "role": "http://modular-medical.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "16", "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "17", "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - LEASES (Tables)", "menuCat": "Tables", "order": "18", "role": "http://modular-medical.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)", "menuCat": "Tables", "order": "19", "role": "http://modular-medical.com/role/StockholdersEquityDeficitTables", "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://modular-medical.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "menuCat": "Tables", "order": "20", "role": "http://modular-medical.com/role/Stock-basedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "modd:DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MachineryAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "menuCat": "Details", "order": "21", "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails", "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "modd:DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MachineryAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "modd:DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails2Abstract", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)", "menuCat": "Details", "order": "22", "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails2", "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "modd:DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails2Abstract", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "p", "modd:ReverseStockSplitPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2021-11-242021-11-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "modd:ReverseStockSplitPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2021-11-242021-11-24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "modd:DisclosureLeasesDetailsAbstract", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - LEASES (Details)", "menuCat": "Details", "order": "24", "role": "http://modular-medical.com/role/LeasesDetails", "shortName": "LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "modd:DisclosureLeasesDetailsAbstract", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "modd:CashPaidforLeaseLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - LEASES (Details Narrative)", "menuCat": "Details", "order": "25", "role": "http://modular-medical.com/role/LeasesDetailsNarrative", "shortName": "LEASES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-10-012022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "p", "modd:PPPNotesPayableTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2020-04-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnsecuredDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - PPP NOTE (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://modular-medical.com/role/PppNoteDetailsNarrative", "shortName": "PPP NOTE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "modd:PPPNotesPayableTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2020-04-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnsecuredDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2021-04-012021-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative", "shortName": "CONVERTIBLE PROMISSORY NOTES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2021-04-012021-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "modd:DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails2Abstract", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details)", "menuCat": "Details", "order": "28", "role": "http://modular-medical.com/role/StockholdersEquityDeficitDetails", "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "modd:DisclosureStockholdersEquityDeficitDetailsAbstract", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31_custom_Warrant1Member", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://modular-medical.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "modd:DisclosureStockBasedCompensationDetailsAbstract", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-10-012022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - STOCK-BASED COMPENSATION (Details)", "menuCat": "Details", "order": "30", "role": "http://modular-medical.com/role/Stock-basedCompensationDetails", "shortName": "STOCK-BASED COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "modd:DisclosureStockBasedCompensationDetailsAbstract", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-10-012022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "modd:DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails2Abstract", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - STOCK-BASED COMPENSATION (Details 2)", "menuCat": "Details", "order": "31", "role": "http://modular-medical.com/role/Stock-basedCompensationDetails2", "shortName": "STOCK-BASED COMPENSATION (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "modd:DisclosureStockBasedCompensationDetails2Abstract", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-03-31_us-gaap_StockOptionMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "modd:DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails2Abstract", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - STOCK-BASED COMPENSATION (Details 3)", "menuCat": "Details", "order": "32", "role": "http://modular-medical.com/role/Stock-basedCompensationDetails3", "shortName": "STOCK-BASED COMPENSATION (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "modd:DisclosureStockBasedCompensationDetails3Abstract", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2022-12-31_us-gaap_StockOptionMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2017-10-012017-10-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "STOCK-BASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2021-08-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2017-10-012017-10-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://modular-medical.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2023-01-012023-01-31_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-10-012022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://modular-medical.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-10-012022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "AsOf2021-03-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2021-04-012021-06-30_us-gaap_CommonStockMember", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://modular-medical.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2021-04-012021-12-31", "decimals": "0", "lang": null, "name": "modd:GainOnPPPNoteForgiveness", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "7", "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies", "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - LEASES", "menuCat": "Notes", "order": "8", "role": "http://modular-medical.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "modd:PPPNotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - PPP NOTE", "menuCat": "Notes", "order": "9", "role": "http://modular-medical.com/role/PppNote", "shortName": "PPP NOTE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "modular_3q23.htm", "contextRef": "From2022-04-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "modd:PPPNotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 14, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r293", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://modular-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "modd_CashPaidforLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cash Paid for Lease Liabilities" } } }, "localname": "CashPaidforLeaseLiabilities", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "modd_CommonStockIssuableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Issuable [Member]" } } }, "localname": "CommonStockIssuableMember", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "modd_DisclosureLeasesDetailsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisclosureLeasesDetailsAbstract", "verboseLabel": "LEASES" } } }, "localname": "DisclosureLeasesDetailsAbstract", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "modd_DisclosurePppNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ppp Note" } } }, "localname": "DisclosurePppNoteAbstract", "nsuri": "http://modular-medical.com/20221231", "xbrltype": "stringItemType" }, "modd_DisclosureStockBasedCompensationDetails2Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK-BASED COMPENSATION (Details 2)" } } }, "localname": "DisclosureStockBasedCompensationDetails2Abstract", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "modd_DisclosureStockBasedCompensationDetails3Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK-BASED COMPENSATION (Details 3)" } } }, "localname": "DisclosureStockBasedCompensationDetails3Abstract", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "modd_DisclosureStockBasedCompensationDetailsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisclosureStockBasedCompensationDetailsAbstract", "verboseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureStockBasedCompensationDetailsAbstract", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "modd_DisclosureStockholdersEquityDeficitDetailsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "DisclosureStockholdersEquityDeficitDetailsAbstract", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "modd_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails2Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)" } } }, "localname": "DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails2Abstract", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "modd_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract", "verboseLabel": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "modd_EarningsPerShareBasicAndDiluted1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted1", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "modd_EarningsPerShareBasicAndDiluted1Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per share" } } }, "localname": "EarningsPerShareBasicAndDiluted1Abstract", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "modd_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares used in computing net loss per share" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "modd_GainOnPPPNoteForgiveness": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gain on PPP note forgiveness" } } }, "localname": "GainOnPPPNoteForgiveness", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "modd_IncreaseDecreaseInLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change in lease liability" } } }, "localname": "IncreaseDecreaseInLeaseLiability", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "modd_IssuableOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "IssuableOfStockAndWarrantsForServicesOrClaims", "verboseLabel": "Shares issuable for services" } } }, "localname": "IssuableOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "modd_IssuanceOfCommonStockAndWarrantsInEquityOfferingNet": { "auth_ref": [], "calculation": { "http://modular-medical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants in equity offering, net", "verboseLabel": "Proceeds from issuance of common stock and warrants, net" } } }, "localname": "IssuanceOfCommonStockAndWarrantsInEquityOfferingNet", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows", "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "modd_IssuanceOfCommonStockAndWarrantsInEquityOfferingNetShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants in equity offering, net, Shares" } } }, "localname": "IssuanceOfCommonStockAndWarrantsInEquityOfferingNetShares", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "modd_OperatingLeasesImputedInterest": { "auth_ref": [], "calculation": { "http://modular-medical.com/role/LeasesDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Imputed interest" } } }, "localname": "OperatingLeasesImputedInterest", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "modd_PPPNotesPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PPP NOTE" } } }, "localname": "PPPNotesPayableTextBlock", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/PppNote" ], "xbrltype": "textBlockItemType" }, "modd_ProceedsFromIssuanceOfPromissoryNote": { "auth_ref": [], "calculation": { "http://modular-medical.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from issuance of promissory note" } } }, "localname": "ProceedsFromIssuanceOfPromissoryNote", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "modd_ReverseStockSplitPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reverse Stock Split" } } }, "localname": "ReverseStockSplitPolicyTextBlock", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "modd_RightOfUseAssetPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset" } } }, "localname": "RightOfUseAssetPolicyTextBlock", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "modd_RisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties" } } }, "localname": "RisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2" ], "xbrltype": "sharesItemType" }, "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2" ], "xbrltype": "sharesItemType" }, "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2" ], "xbrltype": "sharesItemType" }, "modd_SharesIssuableForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issuable for services" } } }, "localname": "SharesIssuableForServices", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "modd_SharesIssuedForReverseStockSplit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for reverse stock split" } } }, "localname": "SharesIssuedForReverseStockSplit", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "modd_Warrant1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 1 [Member]" } } }, "localname": "Warrant1Member", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "modd_Warrant2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 2 [Member]" } } }, "localname": "Warrant2Member", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "modd_Warrant3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 3 [Member]" } } }, "localname": "Warrant3Member", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "modd_Warrant4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 4 [Member]" } } }, "localname": "Warrant4Member", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted1", "verboseLabel": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted1", "nsuri": "http://modular-medical.com/20221231", "presentation": [ "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "srt_MaximumMember": { "auth_ref": [ "r168", "r169", "r170", "r171", "r208", "r257", "r262", "r271", "r272", "r278", "r279", "r281", "r315", "r321", "r322", "r323", "r324", "r325", "r326" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails", "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r168", "r169", "r170", "r171", "r208", "r257", "r262", "r271", "r272", "r278", "r279", "r281", "r315", "r321", "r322", "r323", "r324", "r325", "r326" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails", "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r168", "r169", "r170", "r171", "r207", "r208", "r214", "r215", "r216", "r256", "r257", "r262", "r271", "r272", "r278", "r279", "r281", "r311", "r315", "r322", "r323", "r324", "r325", "r326" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails", "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r168", "r169", "r170", "r171", "r207", "r208", "r214", "r215", "r216", "r256", "r257", "r262", "r271", "r272", "r278", "r279", "r281", "r311", "r315", "r322", "r323", "r324", "r325", "r326" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails", "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r46", "r111" ], "calculation": { "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r117", "r118", "r241", "r242", "r243", "r244", "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure:" } } }, "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r6", "r280" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r217", "r218", "r219", "r307", "r308", "r309", "r317" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r25", "r32", "r76", "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r23", "r189", "r249", "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r79", "r90", "r112", "r124", "r149", "r157", "r159", "r162", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r233", "r235", "r240", "r280", "r313", "r314", "r319" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r107", "r114", "r124", "r162", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r233", "r235", "r240", "r280", "r313", "r314", "r319" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r124", "r162", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r233", "r235", "r240", "r313", "r314", "r319" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "TOTAL NON-CURRENT ASSETS" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r34", "r109", "r273" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets", "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r29", "r75" ], "calculation": { "http://modular-medical.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Common stock warrants" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails2", "http://modular-medical.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r16", "r83", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r48", "r166", "r167", "r268", "r312" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS & CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CommitmentsContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r307", "r308", "r317" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r52" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r5", "r280" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, $0.001 par value, 50,000,000 shares authorized; 10,932,098 and 10,461,898 shares issued and outstanding as of December 31, 2022 and March 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r88", "r144" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r45" ], "calculation": { "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction-in-process" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r3", "r81", "r92", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r2", "r80", "r89", "r99" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r51", "r122", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r192" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "CONVERTIBLE PROMISSORY NOTES" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r304" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Security deposit" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r303" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "verboseLabel": "Security deposit" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r32", "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2", "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r69", "r70", "r71", "r72", "r275" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2", "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r56", "r64" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Schedule of Fair value Assumptions of Options" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r37", "r38" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Per-Share Amounts" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r52", "r105", "r117", "r118", "r119", "r127", "r128", "r129", "r131", "r136", "r138", "r141", "r163", "r206", "r217", "r218", "r219", "r224", "r225", "r238", "r241", "r242", "r243", "r244", "r245", "r246", "r252", "r263", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit", "http://modular-medical.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r73", "r74" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r32", "r49", "r50" ], "calculation": { "http://modular-medical.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Loss on debt extinguishment", "negatedLabel": "Loss on debt extinguishment", "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://modular-medical.com/role/StatementsOfCashFlows", "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r24" ], "calculation": { "http://modular-medical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r21", "r78", "r84", "r98", "r149", "r156", "r158", "r160", "r259", "r277" ], "calculation": { "http://modular-medical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r125", "r221", "r222", "r223", "r226", "r228", "r230", "r231", "r232" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r126", "r137", "r138", "r148", "r220", "r227", "r229", "r261" ], "calculation": { "http://modular-medical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Other assets and prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r77", "r87", "r120", "r147", "r248" ], "calculation": { "http://modular-medical.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r86" ], "calculation": { "http://modular-medical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Other income (expense)" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "verboseLabel": "Shares issued for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r45" ], "calculation": { "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "LEASES" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r124", "r162", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r234", "r235", "r236", "r240", "r276", "r313", "r319", "r320" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r10", "r82", "r94", "r280", "r306", "r310", "r318" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r15", "r108", "r124", "r162", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r234", "r235", "r236", "r240", "r280", "r313", "r319", "r320" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r45" ], "calculation": { "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r121" ], "calculation": { "http://modular-medical.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r121" ], "calculation": { "http://modular-medical.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r29", "r30", "r33" ], "calculation": { "http://modular-medical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r22", "r33", "r85", "r97", "r106", "r115", "r116", "r119", "r124", "r130", "r132", "r133", "r134", "r135", "r137", "r138", "r139", "r149", "r156", "r158", "r160", "r162", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r239", "r240", "r277", "r313" ], "calculation": { "http://modular-medical.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows", "http://modular-medical.com/role/StatementsOfOperations", "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Issued Accounting Pronouncement" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2", "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r19", "r20" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2", "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://modular-medical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r149", "r156", "r158", "r160", "r277" ], "calculation": { "http://modular-medical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r251" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Short-term lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r251" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Long-term lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r250" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of use asset, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r101", "r102" ], "calculation": { "http://modular-medical.com/role/LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r101", "r102" ], "calculation": { "http://modular-medical.com/role/LeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r101", "r102" ], "calculation": { "http://modular-medical.com/role/LeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r36", "r42", "r68" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r26" ], "calculation": { "http://modular-medical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r4", "r193" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r4", "r193" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r4", "r280" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r113", "r164", "r165", "r274" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r28" ], "calculation": { "http://modular-medical.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from issuance of convertible notes, net" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r27" ], "calculation": { "http://modular-medical.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceed from private placement, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r45", "r110" ], "calculation": { "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r47", "r95", "r260", "r280" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets", "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r47", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r67", "r100", "r327" ], "calculation": { "http://modular-medical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r7", "r53", "r93", "r266", "r267", "r280" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r105", "r127", "r128", "r129", "r131", "r136", "r138", "r163", "r217", "r218", "r219", "r224", "r225", "r238", "r263", "r265" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Anti-Dilutive Shares" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in common stock outstanding.", "label": "Schedule of Warrant Outstanding" } } }, "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future minimum Lease Payment" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r58", "r60", "r62" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Stock Option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.", "label": "Schedule of Outstanding and Exercisable Option, Range" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r150", "r151", "r152", "r153", "r154", "r155", "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Reportable Segment" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "General and Administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://modular-medical.com/role/Stock-basedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r209", "r210" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options to purchase common stock", "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails2", "http://modular-medical.com/role/Stock-basedCompensationDetails2", "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r209", "r210" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance", "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2", "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://modular-medical.com/role/Stock-basedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r55", "r65" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "STOCK-BASED COMPENSATION" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r18", "r52", "r105", "r117", "r118", "r119", "r127", "r128", "r129", "r131", "r136", "r138", "r141", "r163", "r206", "r217", "r218", "r219", "r224", "r225", "r238", "r241", "r242", "r243", "r244", "r245", "r246", "r252", "r263", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit", "http://modular-medical.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit", "http://modular-medical.com/role/Stock-basedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r127", "r128", "r129", "r141", "r258" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit", "http://modular-medical.com/role/Stock-basedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of preferred stock and warrants for common stock issued.", "label": "Warrants issued with convertible notes", "verboseLabel": "Fair value of detachable warrants issued with convertible notes" } } }, "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfCashFlows", "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Shares Approved under Equity Incentive Plan", "verboseLabel": "Shares approved under Equity Incentive Plan" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative", "http://modular-medical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r4", "r5", "r52", "r53" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock-based compensation, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Shares issued for services, Shares", "verboseLabel": "Stock Issued During Period, Shares, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit", "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r4", "r5", "r52", "r53" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Private placement of common stock, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Shares issued for reverse stock split, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r4", "r5", "r52", "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Issuance of common stock under equity incentive plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Shares issued for services", "verboseLabel": "Stock Issued During Period, Value, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit", "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r4", "r5", "r52", "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Private placement of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r4", "r5", "r53", "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/Stock-basedCompensationDetails2", "http://modular-medical.com/role/Stock-basedCompensationDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r5", "r8", "r9", "r43", "r280", "r306", "r310", "r318" ], "calculation": { "http://modular-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets", "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r55", "r123", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r237" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/StockholdersEquityDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' Equity, Reverse Stock Split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r247", "r254" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r247", "r254" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r247", "r254" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r247", "r254" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r253", "r255" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Liquidity" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnsecuredDebtCurrent": { "auth_ref": [ "r2", "r80", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.", "label": "Unsecured Debt, Current" } } }, "localname": "UnsecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/PppNoteDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r39", "r40", "r41", "r142", "r143", "r145", "r146" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "https://asc.fasb.org/topic&trid=2208923", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r282": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r283": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r284": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r285": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r286": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r287": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r288": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r289": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r291": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r292": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r293": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r294": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r295": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r296": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r297": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r298": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r299": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r301": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r312": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r36": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 52 0001019056-23-000132-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001019056-23-000132-xbrl.zip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